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ABSTRACT 
 




This dissertation is an exploration of the putative mediators of complicated grief 
treatment (CGT) in an effort to gain a better understanding of the mechanisms by which the 
treatment exerts its effects. This three-paper dissertation utilizes data from an NIMH-funded 
randomized controlled trial of CGT (Shear et al., 2005), which showed that CGT is more 
effective than Interpersonal Psychotherapy (IPT) in reducing symptoms of complicated grief 
(CG).  The first paper examines a broad range of ancillary outcomes including symptoms of 
anxiety, depression, complicated grief and sleep disturbance due to bad dreams.  Antidepressant 
use is examined as a possible moderator since half the sample was taking antidepressants and 
those taking antidepressants had a marginally better response rate in CGT than those not taking 
them (59% vs. 42% in CGT and 40% vs. 19% in IPT). CGT was more effective than IPT in 
reducing cognitive symptoms of anxiety, depression as measured by the Hamilton Rating Scale 
for Depression (HRSD), somatic symptoms of depression, guilt/self-blame, negative thoughts 
about the future, avoidance and poor sleep due to bad dreams. The difference in treatment effect 
on the HRSD for CGT over IPT was more pronounced for participants not taking antidepressants 
where CGT reduced depression but IPT did not. Paper two examines possible mediators specific 
to the model of CGT including: guilt/self-blame specific to the death or deceased; negative 
thoughts about the future; avoidance of reminders of the loss; anxiety and depression (intense 
negative emotions). Antidepressants are also examined as a potential moderator to explore 
whether their use affects the mediating role of the identified variables.  All of these variables 
emerged as either full or partial mediators of CGT. Antidepressant use had no effect on the 
  
   
	   	   	  
mediating role of these variables. Paper three examines whether alliance (measured at week 4) 
predicts subsequent change in grief symptoms (controlling for early symptom change) and if so, 
whether it accounts for the difference in treatment effect between CGT and IPT (mediation). 
Working alliance emerged as a mediator of CGT, accounting for 28% of the treatment effect 
found between CGT/IPT and grief symptoms. Discussion sections for each paper summarize 
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Introduction 
This dissertation is an exploration of the possible mediators of complicated grief 
treatment (CGT) in an effort to gain a better understanding of the mechanisms by which the 
treatment exerts its effects. In a randomized controlled trial it was shown that CGT is more 
effective than Interpersonal Psychotherapy (IPT) in treating complicated grief (CG), a newly 
identified syndrome that causes significant impairment and is associated with a negative course 
without treatment (Shear et al., 2005). The response rate of the intent-to-treat sample (n=95) was 
51% in CGT vs. 28% in IPT, p = .02 and among treatment completers (n=69) the response rate 
was 66% in CGT vs. 32% in IPT, p = .006. Among treatment completers, CGT was also more 
effective in reducing grief symptoms, depression and grief-related impairment in work and social 
functioning.   
Over the past decade, several other clinical trials have examined psychotherapy 
interventions targeting CG and have found positive results (Wagner et al., 2006; P. Boelen et al., 
2007; Rosner et al., 2011). These studies confirm that people with symptoms of complicated 
grief can be effectively treated with the right tools. Identifying which components are the most 
salient and understanding how they work to reduce CG symptoms requires further study.  
Complicated grief is a debilitating condition that affects roughly 7% of bereaved people 
(Kersting, 2011).  It is characterized by persistent symptoms of separation distress (longing and 
yearning for the deceased, intense sadness, preoccupation with thoughts and memories of the 
deceased and loss of interest in activities) and traumatic distress (disbelief and shock, difficulty 
comprehending the loss, feeling lost and disoriented, intrusive images and avoidance of 
reminders of the loss). While not currently a diagnosis in the DSM-IV, CG can be reliably 
  
  2
   
	   	   	  
identified by administering the Inventory of Complicated Grief (ICG) more than six months after 
the death and using a cut-off score of 30 (Prigerson, Bierhals et al., 1995). CG has been 
distinguished from other disorders such as MDD, Anxiety and PTSD (Prigerson, Frank et al., 
1995; P. A. Boelen & van den Bout, 2008).  It has been associated with increased risk for other 
physical and mental health problems such as high blood pressure, cancer, hypertension, suicidal 
ideation and substance abuse (Prigerson et al., 2009).   
CGT is the first targeted treatment for this condition that was manualized and tested in a 
formalized randomized controlled trial (Shear et al., 2005).  The treatment is based on an 
attachment theory framework for understanding bereavement, grief and mourning and the 
complications that impede natural healing. Most typically these include counter-factual thinking 
around troubling aspects of the death (e.g. blaming oneself or others for how the person died) or 
consequence of the death (e.g. life has no purpose or meaning without the loved one); avoidance 
behaviors; and problems with emotion regulation. This results in the syndrome of complicated 
grief. CGT works to identify and resolve the complicating issues (e.g. acceptance vs. 
counterfactual thinking, reducing avoidance, supporting emotion regulation) in order to facilitate 
the natural healing process of fully acknowledging the finality and consequences of the loss and 
re-envisioning life with meaning and satisfaction.  
This dissertation explores the possible mediators of CGT, first by looking broadly at a 
range of ancillary outcomes of the treatment (paper 1) and then more specifically at possible 
mediators related directly to the treatment model (e.g. avoidance, negative thoughts, self-blame, 
etc.) (paper 2). Mediation analysis is becoming increasingly more important as researchers, 
clinicians and funders seek to improve outcomes and efficiency of psychotherapy.  Methodology 
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for establishing mediation has been developed and more psychotherapy studies are incorporating 
potential mediators into their data collection and analyses.  
The primary task in establishing mediation is to demonstrate a strong association between 
the intervention and the mediator and between the mediator and the outcome	  (Baron & Kenny, 
1986). It is also necessary to show that change in the mediator preceded change in the outcome	  
(Johansson & Hoglend, 2007). Establishing temporal precedence can be difficult, as it requires 
measurements at multiple time points during the treatment rather than just at beginning and end. 
Paper 2 examines 5 potential mediators of CGT, following guidelines for establishing mediation 
proposed by Baron and Kenny as well as modifications by the MacArthur work group (Kraemer 
et al., 2008) and taking temporal precedence into account where possible. 
In addition to exploring possible mediators related specifically to the model of CGT, this 
dissertation also examines the role of a non-specific component of the treatment, therapeutic 
alliance (paper 3). Most commonly defined as the agreement between therapist and patient on the 
goals and tasks of therapy as well as the therapeutic bond (Bordin, 1979), the alliance has largely 
been examined in terms of its correlation with outcome, not its role as a mediator of treatment 
effects.  
Alliance has been identified in the literature as one of the most salient components of 
psychotherapy, accounting for significantly more of the variance in outcome than specific 
treatment techniques (Wampold, 2001).  Recent studies have shown that the correlation between 
alliance and outcome holds true across treatment types, patient characteristics, measurement 
scales, raters, time of alliance (early, mid or late), outcome measures, publication source, 
research design, and researcher allegiance (Horvath et al., 2011; Fluckiger, 2012). Only a 
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handful of studies have found that alliance is not associated with treatment gains (Gaston et al., 
1991; Barber et al., 1999; Feeley, 1999; Kaufman et al., 2005).  
One of the critiques of alliance research has been that temporal precedence has been 
overlooked. Alliance, measured late in the treatment, may be associated with outcome but may 
reflect symptom improvement rather than the other way around (Feeley, 1999; Kazdin, 2007). To 
avoid this problem, researchers recommend that alliance be measured early in the treatment and 
that outcome reflect change that occurred after the alliance was measured (Zuroff & Blatt, 2006; 
Kazdin, 2007). More recent studies have used longitudinal designs to examine alliance at 
multiple time points, controlling for earlier symptom change (Barber et al., 2000; Kaufman et al., 
2005; Zuroff & Blatt, 2006; Beckner et al., 2007). Only one study identified by this author has 
examined alliance as a potential mediator of outcome and found that it did not mediate change in 
depression among adolescents treated with CBT because alliance was not associated with 
treatment gains (Kaufman et al., 2005).  
Specific Aims and Hypotheses of the Three Papers 
The overall aim of the dissertation is to enhance our understanding of how CGT works to 
reduce grief. What are the changes within the patient or within the treatment that are associated 
with and account for a reduction in the symptoms of complicated grief? Do specific ingredients 
of the treatment matter most or do non-specific components such as therapeutic alliance matter 
more? This 3-paper dissertation will utilize data from an NIMH-funded randomized controlled 
trial of CGT (Shear et al., 2005). The first paper examines a broad range of ancillary outcomes 
including symptoms of anxiety, depression, complicated grief and sleep disturbance due to bad 
dreams.  Antidepressant use is examined as a possible moderator since half the sample was 
taking antidepressants and those taking antidepressants had a marginally better response rate in 
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CGT than those not taking them (59% vs. 42% in CGT and 40% vs. 19% in IPT). Paper two 
examines possible mediators specific to the model of CGT including: guilt/self-blame specific to 
the death or deceased; negative thoughts about the future; avoidance of reminders of the loss; 
anxiety and depression (intense negative emotions). Antidepressants are also examined as a 
potential moderator to explore whether their use affects the mediating role of the identified 
variables.  Paper three examines whether alliance (measured at week 4) predicts subsequent 
change in grief symptoms (controlling for early symptom change) and if so, whether it accounts 
for the difference in treatment effect between CGT and IPT (mediation). 
Paper 1 
Aim 1: To examine whether treatment type (CGT or IPT) is significantly associated with 
a change in ancillary outcomes including: symptoms of anxiety, depression, complicated grief 
and sleep-related symptoms. 
Hypothesis: CGT will be more effective in reducing symptoms of anxiety, depression, 
complicated grief and sleep-related symptoms than IPT. 
Aim 2: To examine whether antidepressant use moderates the relationship between 
treatment group and ancillary outcome. 
Hypothesis: Those taking medication will have better outcomes in CGT than those not 
taking medication. 
Paper 2 
Aim 1: To examine whether change in intermediary variables (ancillary outcomes identified in 
paper 1) is associated with a change in grief symptoms. These include: self-blame related to the 
death or deceased; negative thoughts about the future; anxiety; depression; and avoidance of 
reminders of the loss. 
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Hypothesis: A reduction in each of the intermediary variables (individually) will be 
associated with a reduction in grief. 
Aim 2: To identify which of the intermediary variables can be considered mediators of the 
treatment effect found between CGT/IPT and grief symptoms and to quantify the magnitude of 
their mediating effect.  
Hypothesis: Each of the intermediary variables will be considered mediators of the 
treatment effect found between CGT/IPT and grief symptoms.  
Aim 3: To examine whether antidepressant use affects the mediating relationship between 
intermediary variables and treatment outcome. 
Hypothesis: The mediating role of each intermediary variable will be stronger for those 
not taking antidepressants than for those taking them.  
Paper 3 
Aim 1: To examine whether treatment type is associated with early therapeutic alliance 
(measured at week 4). 
Hypothesis: Treatment type will not be associated with early therapeutic alliance. 
Aim 2: To examine whether early working alliance is associated with a reduction in grief 
symptoms. 
Hypothesis: Early working alliance will be associated with a change in grief symptoms. 
Aim 3: To examine whether alliance can be considered a mediator of the treatment effect found 
between CGT/IPT and grief symptoms and to quantify the magnitude of its mediating effect.  
Hypothesis: Early working alliance will not be considered a mediator of the treatment 
effect found between CGT/IPT and grief symptoms. 
  
  7
   
	   	   	  
 Research to date has shown that treatments designed to treat CG can be successful but we 
do not yet know exactly how they work.  This dissertation will address this gap in the literature 
by examining potential mediators of an efficacious treatment, CGT. Identifying the ancillary 
outcomes and possible mediators of CGT will provide us with valuable information that may 
help to explain how this treatment works to reduce the debilitating symptoms of CG. Researchers 
can use this information to study these variables more closely and incorporate them into future 
research studies designed specifically to test the mediators and mechanisms of action of CGT.  
Ultimately, practitioners will be able to use the findings to hone in on the most salient aspects of 
the treatment, thereby making therapy for CG more potent and efficient.  
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Paper 1: Ancillary Outcomes of Complicated Grief Treatment 
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Introduction 
The loss of a loved one is one of the most difficult experiences a person can endure.  
While most move successfully through a normal grief process, roughly 7% of bereaved people 
develop a debilitating condition known as complicated grief (CG)	  (Kersting, 2011).  CG is 
characterized by persistent yearning and longing for the deceased; intense sorrow and emotional 
pain; preoccupation with thoughts of the loved one and circumstances of the death; a sense of 
disbelief and shock regarding the death; anger and bitterness over the death; maladaptive 
appraisals (self-blame) about oneself in relation to the deceased or the death; excessive 
avoidance of situations and activities that serve as reminders of the loss; feelings of detachment 
from other people since the death; and the feeling that life is meaningless or empty without the 
deceased  (American Psychiatric Association, 2011).   
Although some of the symptoms of CG overlap with disorders sharing similar features, 
studies have distinguished it from major depression, anxiety and post-traumatic stress disorder	  
(Prigerson, Frank et al., 1995; Shear et al., 2005; P. A. Boelen & van den Bout, 2008).  
Additionally, studies show that treatments for depression have minimal effect on symptoms of 
CG	  (Shear et al., 2011).  Complicated grief has been associated with increased risk for cancer, 
high blood pressure, suicidal ideation, hypertension and substance abuse	  (Prigerson et al., 2009).  
Diagnostic criteria for CG have been proposed for the Diagnostic Statistical Manual of Mental 
Disorders (DSM-5) and will likely be included in the section on disorders requiring further study 
as a “complex persistent bereavement-related disorder” (American Psychiatric Association, 
2011).  
Over the past decade, there has been growing interest in the treatment of CG and several 
clinical trials that have examined psychotherapy interventions (Shear et al., 2005; Wagner et al., 
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2006; P. Boelen et al., 2007).  Outcomes have focused primarily on grief symptoms but have also 
included measures of anxiety, depression, impairments in social and work functioning, general 
mental and physical health, general psychopathology, negative cognitions, avoidance behavior 
and sleep quality.  In the first large randomized controlled trial of psychotherapy targeting 
symptoms of CG, Shear et al. (2005) found a significant reduction in CG symptoms in those 
treated with Complicated Grief Treatment (CGT) compared to Interpersonal Psychotherapy 
(IPT). The study also found a decrease in depression and social and work impairment among 
treatment completers (Shear et al., 2005). Utilizing the same data, Germain et al. (2006) found 
that treatment responders showed modest but statistically significant improvements in sleep 
quality.   
In a study by Boelen and colleagues comparing the effectiveness of Cognitive Behavioral 
Treatment (CBT) with supportive counseling for the treatment of CG, results showed a 
significant reduction in CG symptoms and general psychopathology in the CBT groups 
compared to the control (P. Boelen et al., 2007). In a subsequent study utilizing the same data, 
the authors found a significant reduction in loss-related negative cognitions and avoidance 
behavior (P. Boelen et al., 2011).  
Wagner et al. (2006) investigated the effectiveness of an internet-based cognitive-
behavioral therapy for people with CG and found significant improvement in symptoms of 
intrusion, avoidance, maladaptive behavior and general psychopathology. In a study by Rosner 
and colleagues comparing a CG group intervention with treatment as usual (TAU) in an inpatient 
setting, results showed a significant reduction in grief symptoms in the treatment group 
compared with the control while changes in depression and overall mental distress did not differ 
between the two groups (Rosner et al., 2011).  
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The present study is intended to add to this literature by examining ancillary outcomes 
from the 2005 efficacy study of CGT conducted by Shear and colleagues (Shear et al., 2005).  
Aim 1 was to examine symptoms that can interfere with the natural grief process such as anxiety 
and depression as well as the most common form of grief complications such as negative 
thoughts about the future, guilt-related to the death or deceased and grief-related avoidance. Poor 
sleep quality due to bad dreams was included as an extension of prior research on the impact of 
CGT on overall sleep quality and associated subgroups (Germain et al., 2005). Because CGT 
targets specific grief complications such as counterfactual thinking around troubling aspects of 
the death (e.g. self blame for how the person died), avoidance behavior and emotion regulation, 
it was hypothesized that the symptoms identified in this report would respond better to CGT than 
to IPT. Aim 2 was to examine antidepressant use as a possible moderator since nearly half the 
sample was taking at least one antidepressant and results from the parent study showed that 
people taking antidepressants had marginally better response rates in CGT than those not taking 
them. It was hypothesized that those taking antidepressants would have better outcomes (i.e. 
greater reduction in symptoms) in CGT in the present study as well. 
The utility in looking at outcomes above and beyond grief symptoms is that it may 
provide us with more information about the types of symptoms that can be effectively treated 
with this therapeutic approach (with and without concomitant antidepressants). This information 
could be used for future intervention studies targeting CG or other related disorders.  
Overview of parent study 
Details of the methodology of the parent study are available in a previously published 
paper (Shear et al., 2005). Briefly, participants were recruited through professional referral, self-
referral and media announcements between 2001 and 2004 in Pittsburgh, PA at a university-
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based psychiatric clinic as well as a satellite clinic in a low-income African-American 
community. The randomized sample included 83 women and 12 men (age 18-85) who had lost a 
loved one at least 6 months prior and met criteria for complicated grief, defined as a score of 30 
or higher on the Inventory of Complicated Grief (ICG)	  (Prigerson, Bierhals et al., 1995).  
Participants were randomly assigned to receive IPT, n=46, or CGT, n = 49. Randomization was 
stratified by and within treatment site and by violent (accident, homicide or suicide) vs. non-
violent death of a loved one.  Both groups were offered 16 weekly therapy sessions over a 16 to 
20 week period.   Medication for longer than 3 months at a stable dose for > 6 weeks was 
permitted as long as the medication management was transferred to the study pharmacotherapist. 
All therapists were either masters or doctoral level clinicians with training and certification in 
either IPT or CGT.  Therapists received ongoing supervision and therapy sessions were audio 
taped for adherence, performed on a randomly selected subset of session segments.  Analysis of 
the adherence data showed that the two treatments could be reliably distinguished from one 
another (Wilsey et al., 2006).  Data was collected by self-report and independent evaluators 
blinded to treatment assignment at baseline, during treatment and posttreatment follow-up.  The 
primary outcome measure was the Clinical Global Impression of Improvement Scale (CGI), a 
single Likert-type rating from 1 to 7 where 1 through 3 indicate “very much,” “much” and 
“minimally improved” respectively; 4 indicates “no change” and 5 through 8 indicate 
“minimally,” “much” and “very much worse” respectively (Guy, 1976).  A CGI rating of 1 or 2 
“very much” or “much improved” qualified the participant as a treatment responder.  Additional 
outcome measures included the Inventory of Complicated Grief (ICG), Beck Anxiety Inventory 
(BAI), Beck Depression Inventory (BDI) and Work and Social Adjustment Scale (WSAS).  
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The control condition, IPT, is a manualized short-term treatment that focuses on a 
selected problem area of grief, interpersonal disputes, role transition or interpersonal deficits. 
Most of the IPT treatments in this study focused on grief alone or grief and one of the other 
problem areas. 
The treatment condition, CGT, was also delivered according to a treatment manual and 
had yielded positive results in a prior pilot study (Shear et al., 2001). CGT is based on an 
attachment theory model of grief. It integrates IPT with cognitive-behavioral techniques used to 
address trauma-like symptoms of CG and motivational interviewing techniques. Unlike IPT, 
CGT includes grief monitoring, psychoeducation about CG and the techniques used to address it; 
exposure techniques such as imaginal revisiting (repeated retelling of the story of the death), 
situational revisiting (graded exposure to avoided situations) and an imaginal conversation with 
the deceased; a focus on personal aspirations and goals and a focus in each session on the dual 
process of adjustment to the loss and restoration of a satisfying life. 
Results of the RCT (Shear et al., 2005) showed the response rate was greater in CGT than 
IPT (51% compared to 28% for IPT (p=.02)) and time response (to a 20 point or better 
improvement on the ICG) was faster for CGT. Among treatment completers, 66% of CGT 
participants responded to treatment compared with 32% in IPT. The number needed to treat was 
2.9 for completers. Among treatment completers, CGT was also significantly more effective than 
IPT in reducing complicated grief symptoms (ICG), depression (BDI), and improving grief-





   
	   	   	  
This study examined treatment completers only (n=69, 35 in CGT and 34 in IPT) in order 
to examine ancillary outcomes among those who completed the full course of treatment. 
Completers did not differ from drop-outs on any of the baseline measures. The majority of the 
sample was female (84%), Caucasian (74%) with a mean age of 48.4 years. Nearly half the 
sample was taking antidepressant medication (49%) and comorbid mood or anxiety disorders 
were common. Forty-six percent had current major depressive disorder (MDD), 52% current 
posttraumatic stress disorder (PTSD), 18% current generalized anxiety disorder (GAD), 10% 
current panic disorder (PD), 3% current social phobia disorder, and 6% current obsessive-
compulsive disorder (OCD).  See Table 1 for baseline comparison of completers by treatment 
group.  
Ancillary Outcome Measures 
Anxiety Symptoms – Anxiety symptoms were measured using two different instruments: 
the Beck Anxiety Inventory (BAI) and the Structured Clinical Interview for the DSM-IV (SCID). 
BAI: Treatment effects on the BAI, a 21-item, well-validated instrument used to measure 
clinical anxiety	  (Beck et al., 1988) were shown in the parent study; among completers, the 
change in mean BAI score was 9.5 in CGT vs. 5.8 in IPT, p = .17 (Shear et al., 2005). In this 
analysis, this work is extended to examine whether the treatment differentially affected cognitive 
and somatic subscales. 
Cognitive Subscale:  A composite of items from the BAI (described above) was used to 
measure the cognitive aspects of anxiety identified by Hewitt and Norton who found two factor 
loadings for the BAI; cognitive and somatic (Hewitt & Norton, 1993). The items that loaded 
highest on the cognitive factor (and lowest on the somatic factor) include: fear of the worst 
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happening, terrified, nervous, fear of losing control, fear of dying, and scared. Internal 
consistency for the composite variable (using this sample) was high (Cronbach’s α = .89).   
Somatic Subscale:  This variable, derived from the BAI (described above), includes items 
that loaded highest on the somatic factor and lowest on the cognitive factor (Hewitt & Norton, 
1993): face flushed, feeling hot, numbness or tingling, dizzy or lightheaded, wobbliness in legs, 
sweating, heart racing or pounding, unsteady, difficulty breathing, faint, indigestion, and 
feelings of choking. Cronbach’s α in this sample = .88.   
SCID: Change in anxiety disorder diagnoses was evaluated for those disorders endorsed 
by more than 10% of the completer sample. This included Generalized Anxiety Disorder (GAD) 
and Post Traumatic Stress Disorder (PTSD), measured by the SCID (First et al., 1996).  
Depressive Symptoms – Depressive symptoms were measured using 3 different 
instruments: the Beck Depression Inventory (BDI), the Hamilton Rating Scale for Depression 
(HRSD) and the SCID. 
BDI: The BDI is a widely used, well-validated 21-item self-report instrument used to 
assess the severity of depression (Beck et al., 1979). Treatment effects on the BDI were shown in 
the parent study. Among treatment completers, the change in mean BDI score was 12.7 in CGT 
vs. 7.3 in IPT, p = .02 (Shear et al., 2005). In this analysis, this work is extended to examine 
whether the treatment differentially affected cognitive and somatic-affective subscales (Steer et 
al., 1999). All items on the BDI are scored from 0 to 3, with 3 = the most symptomatic and 0 = 
the least. 
Cognitive Subscale: A composite of items from the BDI was used to measure cognitive 
aspects of depression including: pessimism, past failure, guilty feelings, punishment feelings, 
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self-dislike, self-criticalness, suicidal thoughts or wishes, crying and worthlessness. Cronbach’s 
α in this sample = .86.   
Somatic-Affective Subscale: This variable, derived from the BDI (described above), 
includes items that loaded highest on the somatic-affective factor: loss of pleasure, loss of 
interest, indecisiveness, loss of energy, irritability, change in appetite, tiredness and fatigue, and 
loss of interest in sex. Lack of concentration also loaded high on this factor but was not included 
in this analysis because it is not in the 21-item version of the BDI. Cronbach’s α in this sample = 
.81.   
Guilt/self-blame (general): This variable was derived from one item on the BDI 
(described above). This item asks the respondent to select the statement which best describes the 
way he/she has been feeling in the past week: I don’t feel particularly guilty; I feel guilt a good 
part of the time; I feel quite guilty most of the time; I feel guilty all of the time. This variable 
measures guilt in general and was moderately correlated with the grief –specific guilt measure 
derived from the SCI-CG (r=.53). 
Negative thoughts about the future: This variable was measured by one item on the BDI 
(described above), which asks the respondent to select the statement that best describes the way 
he/she has been feeling in the past week: I am not particularly discouraged about the future; I 
feel discouraged about the future; I feel I have nothing to look forward to; I feel that the future is 
hopeless and that things cannot improve. 
HRSD: The Hamilton Rating Scale for Depression (HRSD) is a widely used, well-
validated 25-item interview-rated instrument used to assess the severity of depression (Hamilton, 
1960). The total score was used to measure depression. 
SCID: Major Depressive Disorder (MDD) was measured by the SCID (First et al., 1996). 
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Complicated Grief Symptoms – Symptoms of CG were measured by variables created 
from two different instruments: the GRAQ and the SCI-CG. 
Avoidance (GRAQ): This variable was measured by the total score on the Grief Related 
Avoidance Questionnaire (Shear et al., 2007). This 15-item self-report questionnaire was 
developed and tested by Shear’s research team to assess the level of grief-related avoidance of 
common situations and activities following the death.  Each item is scored from 0 to 4 with 0 = 
never, 1 = rarely, 2 = sometimes, 3 = often and 4 = always. The scale has good psychometric 
properties (α = .87) and CG patients endorse a range of scores on the scale.  
Avoidance of the loss subscale: This variable was derived from the GRAQ (described 
above), a composite of 6 items that pertain specifically to reminders of the deceased: Do you 
avoid rooms or places that you associate with the person who died? Do you avoid activities 
around your home associated with the person who died? Do you have activities outside your 
home that are associated with the person who died? Do you avoid activities with family members 
or friends that are associated with the person who died? Do you avoid social activities with 
friends that are associated with the person who died? Do you avoid social activities with couples 
or other groups that provoke feelings of being “odd man out” or feelings of intense longing for 
the person who died? In a study by Shear et al.	  (2007), this subscale was significantly correlated 
with the Work and Social Adjustment Scale, which measures functional impairment. Cronbach’s 
α = .87.   
Avoidance (SCI-CG): This variable was derived from the Structured Clinical Interview 
for Complicated Grief (SCI-CG), developed and tested by Shear et al.’s research group. A 
composite of two items from the SCI-CG was used to measure avoidance behavior: “Do you 
avoid activities, people, places, or objects that remind you of ____?”  and “Do you feel reluctant 
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to talk about  ____?” Items are rated from 0 to 2 with 0 = no, 1 = maybe 2 = yes. Cronbach’s α = 
.48.   
Guilt/self-blame related to the death or the deceased: This variable was derived from the 
SCI-CG (described above). A composite of the following items was used: Have you had guilty or 
self-blaming thoughts or beliefs about the death? Do you blame yourself for doing or not doing 
something either when _____ was alive, or at the time he/she died, that you think might have 
helped? Do you have the idea that you could have prevented this death, even though you know it 
isn’t very rational? Cronbach’s α = .86.   
Sleep-related Symptoms – In a study by Germain and colleagues examining the effects of 
CGT on sleep quality, no significant differences were found between treatment groups on overall 
sleep quality or any of the seven subscales of the Pittsburgh Sleep Quality Index (PSQI), 
however statistically significant but modest improvement in sleep quality was found for CGT 
responders (Germain et al., 2006). This work is extended to examine the effects of CGT on sleep 
quality due to bad dreams specifically.   
Bad dreams: This variable was derived from one item on the PSQI, a 19-item self-report 
instrument that measures seven aspects of sleep quality (subjective sleep quality, sleep latency, 
duration, efficiency, disturbances, use of sleep medication and daytime dysfunction) in the past 
month. The item asks the respondent: During the past month, how often have you had trouble 
sleeping because you had bad dreams? Each item rates the frequency of symptoms from 0 to 3 
with 0 = not in the past month, 1 = less than once a week, 2 = once or twice a week and 3 = 3 or 




   
	   	   	  
Differences in baseline characteristics between treatment groups were tested using 
Fisher’s exact test (categorical characteristics) or two-sample t-tests (continuous characteristics). 
Hypothesizing that improvements in ancillary outcomes would be greater in the CGT group 
compared to the IPT group, one-tailed t-tests were used to test for improvements from baseline to 
week 16 (post-treatment) in each ancillary outcome between treatment groups. Although this 
method can inflate the type-1 error rate, this decision was made based on findings from the 
parent study that CGT was more effective than IPT in reducing symptoms of CG and depression 
in the completer sample and trended toward efficacy with regard to reducing anxiety (Shear et 
al., 2005). In addition, the model of CGT targets these variables specifically, providing further 
justification for the hypothesis that CGT would produce greater effects on these outcomes than 
IPT. Statistical significance was set at p<=0.05.  Change in ancillary outcomes within treatment 
groups were tested with paired t-tests and mean changes within treatment groups were 
standardized to facilitate comparison across different outcomes (referred to in Table 2 as 
“standardized change” by dividing the mean change (baseline to post-treatment) by the pooled 
baseline standard deviation. For dichotomous outcomes McNemar’s test was used to test for 
changes within treatment group. Effect size (ES) for the treatment differences between groups 
was calculated by dividing the mean difference in outcome (baseline to post-treatment) by the 
pooled baseline standard deviation. The Wilks-Shapiro test was used to check change variables 
for large departures from normality.  Where found, sensitivity analysis was done to assess the 
robustness of the p-values by additionally performing the Wilcoxin signed rank test. 
To test for moderation of effects by antidepressant use, multiple regression analysis was 
used to examine the interaction between antidepressant use and treatment group as it affects 
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change in ancillary outcomes. For interaction tests, the more liberal p-value of 1.0 was used for 
statistical significance due to the difficulty of detecting interaction effects.  
Results 
Baseline characteristics 
Table 1 includes demographic characteristics of the sample of treatment completers.  The 
sample was 84% female, 74% Caucasian, 22% African-American, 3% Asian, with a mean age of 
48.4 years.  Mean ICG score was 44.8.  Comorbid mood or anxiety disorders were common. 
Forty-six percent had current major depressive disorder (MDD), 52% current posttraumatic 
stress disorder (PTSD), 18% current generalized anxiety disorder (GAD), 10% current panic 
disorder (PD), 3% current social phobia disorder, and 6% current obsessive-compulsive disorder 
(OCD). Thirty-four out of 69 (49%) were taking antidepressant medication.  
There were no significant differences in demographic characteristics or ancillary 
outcomes between the two randomized groups at baseline.  
Table 1. Baseline Comparison of Treatment Groups (n=69) 





Sample Characteristics    
                    Male  5 (14) 6 (18) .75 
                    White         24 (69) 26 (77) .59 
                    Age, mean (SD) 52 (13.4) 48 (11.4) .20 
                    Medication (at least one) 22 (63) 15 (44) .15 
                    Major Depressive Disorder        18 (53)B 13 (38) .33 
                    Posttraumatic Stress Disorder        19 (56)B 16 (47) .47 
                    Generalized Anxiety Disorder 6 (18) 6 (18) 1.0 
                    Panic Disorder 5(14) 2(6) .43 
                    Social Phobia          1 (3)B 1 (3) 1.0 
                    Obsessive Compulsive Disorder 4 (11)B 0 (0) .11 
                    Inventory of Complicated Grief, mean (SD) 46.1 (8.5) 43.4 (9.8) .21 
                    Work and Social Adjustment Scale, mean (SD) 21.9 (10.8) 20.5 (9.6) .56 
                    Beck Depression Inventory, mean (SD) 25.6 (10.9) 21.8 (9.9) .14 
                    Beck Anxiety Inventory, mean (SD) 17.7 (12.6) 14.5 (9.8) .25 
                    Hamilton Rating Scale for Dep., mean (SD)          19.1 (7.0) 16.8 (6.8) .18 
                    Sleep Quality (Global)D, mean (SD) 8.4 (3.4)B 8.8 (4.1)C .64 
A Data are expressed as No. (%) unless otherwise noted. 
B n=34 due to missing data 
C n=33 due to missing data 




   
	   	   	  
Changes in Psychological Symptoms Baseline to Post-Treatment 
Figures 1 – 3 show standardized changes in ancillary outcomes within treatment groups. 
Table 2 shows pre and post treatment scores by treatment group, standardized change within 
groups and effect sizes for the treatment differences. 
Changes in Anxiety Symptoms  
Cognitive symptoms of anxiety (measured by the BAI) showed large decreases 
significantly in both treatment groups but the change was greater in CGT than IPT (1.01 
standardized change in CGT vs. 0.55 standardized change in IPT, treatment effect size (ES) = 
0.45, p = .02). Somatic symptoms of anxiety (BAI) also significantly decreased in both groups 
(0.42 in CGT vs. 0.43 in IPT) but there was no difference between the groups (ES = .02, p = 
0.53). GAD (DSM-IV) did not significantly decrease in either group while PTSD (DSM-IV) 
significantly decreased by 35% in CGT and by 23% in IPT, although the difference between 
treatment groups was not statistically significant.  
Changes in Depressive Symptoms  
Depressive symptoms measured by the HRSD showed large decreases significantly in 
CGT compared to no significant change in IPT (1.2 standardized change in CGT vs. 0.12 
standardized change in IPT, treatment ES = 0.99, p = .0002). Cognitive symptoms of depression 
(measured by the BDI) showed decreases significantly in both groups (0.75 in CGT vs. 0.49 in 
IPT) but the change was marginally greater in CGT (ES = 0.29, p = .06). Somatic-affective 
symptoms of depression (BDI) also decreased in both groups (.83 in CGT vs. 0.52 in IPT) but 
the change in CGT was greater (ES = 0.34, p = .05). MDD (DSM-IV) significantly decreased by 
35% in CGT while the change of 15% in IPT was not significant.   
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Guilt not-related to the death (measured by the BDI) showed large decreases significantly 
in both groups but the change was greater in CGT than IPT (0.81 standardized change in CGT 
vs. 0.33 standardized change in IPT, ES = .48, p = .01). This difference became marginally 
significant (.06) when using the non-parametric Wilcoxin signed rank test to account for the non-
normal distribution of this variable. 
Negative thoughts about the future showed large decreases significantly in both treatment 
groups but the change was greater in CGT than IPT (1.01 standardized change in CGT vs. 0.47 
standardized change in IPT, ES = 0.45, p = .01).  
Change in Complicated Grief Symptoms  
Avoidance (measured by the GRAQ) showed large decreases significantly in CGT 
compared to no significant change in IPT (0.72 standardized change vs. 0.25 standardized 
change, treatment ES = 0.47, p = .05). Both group showed decreases significantly on the 
avoidance of the loss subscale but the difference between the groups was not significant (.56 in 
CGT vs. .39 in IPT, ES = .18, p=.28). Avoidance (measured by the SCI-CG) showed large 
decreases significantly in both groups, with a marginally greater change in CGT compared to 
IPT (1.43 standardized change in CGT vs. .94 standardized change in IPT, ES = .52, p = .06). 
Guilt/self-blame related to the death (measured by the SCI-CG) showed large decreases 
significantly in both groups but the difference between groups was not statistically significant 
(1.17 standardized change in CGT vs. .77 standardized change in IPT, ES = .41, p = .08).  
Change in Sleep-Related Symptoms  
The frequency of bad dreams decreased significantly in CGT while in IPT it remained the 
same. In CGT, the percentage of participants who had bad dreams in the past month decreased 
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from 56% (19/34) to 34% (11/32) while in IPT, the percentage who had bad dreams decreased 
from 51.5% (17/33) to 50%  (16/32).  
Figure 1. Change in Anxiety Symptoms by Treatment Group 
 
Note: Standardized change is calculated as baseline score – post-treatment score/pooled baseline standard deviation. Changes in 
GAD and PTSD are not standardized; they are shown as % change. 
* Difference in treatment effect is statistically significant (p<=.05). 
Change in the BAI total score was previously published by Shear et al. (2005) and is included here for reference. 
 
Figure 2. Change in Depressive Symptoms by Treatment Group 
 
Note: Standardized change is calculated as baseline score – post-treatment score/pooled baseline standard deviation. Change in 
MDD is not standardized; it is shown as % change. 
* Difference in treatment effect is statistically significant (p<=.05). 
Change in the BDI total score was previously published by Shear et al. (2005) and is included here for reference. 
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Figure 3. Change in Complicated Grief Symptoms by Treatment Group 
 
Note: Standardized change is calculated as baseline score – post-treatment score/pooled baseline standard deviation. 
* Difference in treatment effect is statistically significant (p<=.05). 
	  
Table	  2.	  Pre	  and	  Posttreatment	  Scores	  by	  Group	  &	  Effect	  Sizes	  for	  Treatment	  Differences	  
Variables	   	   	  
	   CGT	   IPT	   Effect	  SizeA	   P-­‐ValueB	  
	   Mean	  (SD)	   Mean	  (SD)	   	   	  
Anxiety	  Symptoms	   	   	   	   	  
	  	  	  	  	  	  	  	  	  	  Cognitive	  (BAI)	   n=35	   n=34	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Pretreatment	   7.8	  (4.4)	   6.4	  (4.1)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Posttreatment	   4.5	  (4.9)	   4	  (4.1)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Change	   4.3	  (3.2)	   2.4	  (4.5)	   .45	   .02	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Standardized	  changeC	   1.01	   .55	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P-­‐value	  of	  stand.	  change	   .00	   .00	   	   	  
	  	  	  	  	  	  	  	  	  	  	  Somatic	  (BAI)	   n=35	   n=34	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Pretreatment	   6.2	  (5.8)	   6.0	  (5.1)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Posttreatment	   4.0	  (5.8)	   3.7	  (4.4)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Difference	   2.2	  (3.8)	   2.3	  (3.9)	   .02	   .53	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Standardized	  change	   .42	   .43	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P-­‐value	  of	  stand.	  change	   .00	   .00	   	   	  
	  	  	  	  	  	  	  	  	  	  GAD	  (DSM-­‐IV)D	   	   	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Pretreatment	   6/32	  (19%)	   6/34	  (18%)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Posttreatment	   5/32	  (16%)	   5/34	  (15%)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Change	   1	  (3%)	   1	  (3%)	   0%E	   .50	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P-­‐value	  	   .71	   .32	   	   	  
	  	  	  	  	  	  	  	  	  	  PTSD	  (DSM-­‐IV)D	   	   	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Pretreatment	   18/32	  (56%)	   16/34	  (47%)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Posttreatment	   7/32	  (22%)	   8/34	  (24%)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Change	   11	  (34%)	   8	  (23.5%)	   10.5%E	   .23	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P-­‐value	  	   .01	   .02	   	   	  
Depressive	  Symptoms	   	   	   	   	  
	  	  	  	  	  	  	  	  	  	  HRSD	   n=35	   n=34	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Pretreatment	   19.3	  (6.6)	   16.8	  (6.8)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Posttreatment	   11.2	  (8.3)	   15.4	  (8.5)	   	   	  
0.72	   0.56	  
1.43	  
1.17	  
0.25	   0.39	  




















   
	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Change	   8.1	  (7.6)	   1.4	  (7.2)	   .99	   .00	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Standardized	  change	   1.2	   .21	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P-­‐value	  of	  stand.	  change	   .00	   .13	   	   	  
	  	  	  	  	  	  	  	  	  	  	  Cognitive	  (BDI)	   n=35	   n=34	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Pretreatment	   9.5	  (5.9)	   8.6	  (5.6)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Posttreatment	   5.2	  (5.2)	   5.8	  (5.9)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Change	   4.3	  (4.0)	   2.8	  (3.6)	   .29	   .06	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Standardized	  change	   .75	   .49	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P-­‐value	  of	  stand.	  change	   .00	   .00	   	   	  
	  	  	  	  	  	  	  	  	  	  Somatic-­‐Affective	  (BDI)	  	   n=35	   n=34	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Pretreatment	   10.9	  (5.3)	   9.3	  (5.1)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Posttreatment	   6.6	  (5.6)	   6.6	  (5.0)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Change	   4.3	  (4.6)	   2.7	  (3.8)	   .34	   .05	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Standardized	  change	   .83	   .52	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P-­‐value	  of	  stand.	  change	   .00	   .00	   	   	  
	  	  	  	  	  	  	  	  	  	  Guilt	  General	  -­‐	  BDI	  	   n=35	   n=34	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Pretreatment	   1.1	  (.9)	   .82	  (.83)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Posttreatment	   .45	  (.66)	   .53	  (.9)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Change	   .71	  (.79)	   .29	  (.76)	   .48	   .01F	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Standardized	  change	   .81	   .33	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P-­‐value	  of	  stand.	  change	   .00	   .02	   	   	  
	  	  	  	  	  	  	  	  	  	  Negative	  Thoughts	  	   n=35	   n=34	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Pretreatment	   1.4	  (.9)	   1.1	  (.83)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Posttreatment	   .51	  (.66)	   .68	  (.81)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Change	   .89	  (.96)	   .41(.61)	   .55	   .01	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Standardized	  change	   1.01	   .47	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P-­‐value	  of	  stand.	  change	   .00	   .00	   	   	  
	  	  	  	  	  	  	  	  	  	  	  MDD	  (DSM-­‐IV)D	   	   	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Pretreatment	   17/32	  (53%)	   13/34	  (38%)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Posttreatment	   6/32	  (19%)	   8/34	  (23.5%)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Change	   11	  (34%)	   5	  (15%)	   19%E	   .07	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P-­‐value	  	   .00	   .13	   	   	  
Grief-­‐Related	  Symptoms	   	   	   	   	  
	  	  	  	  	  	  	  	  	  	  Avoidance	  -­‐	  GRAQ	  	   n=29	   n=25	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Pretreatment	   25.5	  (11.1)	   21.4	  (12.8)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Posttreatment	   16.9	  (12.6)	   18.5	  (15.6)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Difference	   8.6	  (14.9)	   3.0	  (9)	   .47	   .05	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Standardized	  change	   .72	   .25	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P-­‐value	  of	  stand.	  change	   .00	   .06	   	   	  
	  	  	  	  	  	  	  	  	  	  	  Avoidance	  of	  Loss	  Subscale	   n=30	   n=25	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Pretreatment	   9.9	  (6)	   9.1	  (6.1)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Posttreatment	   6.5	  (5.9)	   6.8	  (7.1)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Difference	   3.4	  (7.9)	   2.3	  (5)	   .18	   .28	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Standardized	  change	   .56	   .39	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P-­‐value	  of	  stand.	  change	   .01	   .01	   	   	  
	  	  	  	  	  	  	  	  	  	  Avoidance	  -­‐	  SCI-­‐CG	  	   n=27	   n=30	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Pretreatment	   2.7	  (1.2)	   2.4	  (1.2)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Posttreatment	   1	  (1.3)	   1.3	  (1.4)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Difference	   1.7	  (1.4)	   1.1	  (1.3)	   .52	   .06	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Standardized	  change	   1.43	   .94	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P-­‐value	  of	  stand.	  change	   .00	   .00	   	   	  
	  	  	  	  	  	  	  Guilt/Self-­‐Blame	  -­‐	  	  SCI-­‐CG	  	   n=25	   n=31	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Pretreatment	   4.5	  (2.2)	   4.4	  (2.2)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Posttreatment	   1.9	  (1.9)	   2.7	  (2.5)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Change	   2.6	  (2.1)	   1.7	  (2.6)	   .41	   .08	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Standardized	  change	   1.17	   .77	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P-­‐value	  of	  stand.	  change	   .00	   .00	   	   	  
Sleep-­‐Related	  Symptoms	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  Bad	  Dreams	  -­‐	  PSQI	   n=32	   n=31	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Pretreatment	   .97	  (1.1)	   .84	  (1.0)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Posttreatment	   .47	  (.72)	   .87	  (1.0)	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Difference	   .5	  (1.0)	   -­‐.03	  (.87)	   .45	   .02	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Standardized	  change	   .50	   .03	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P-­‐value	  of	  stand.	  change	   .00	   .58	   	   	  
A	  Effect	  size	  of	  treatment	  is	  calculated	  following	  Cohen’s	  D,	  i.e.	  (CGT	  mean	  Diff	  –	  IPT	  mean	  Diff)/	  pooled	  baseline	  standard	  
deviation	  of	  measure),	  for	  example,	  for	  Guilt/Self-­‐blame	  (SCI-­‐CG)	  we	  have	  (2.6	  –	  1.7)/	  sqrt((2.2)^2	  +	  30*(2.2)^2)/(24+30))	  =	  
0.41.	  For	  dichotomous	  outcomes	  (GAD,	  PTSD,	  MDD)	  difference	  in	  %	  change	  is	  listed	  instead	  of	  ES.	  
B	  p-­‐value	  for	  one-­‐sided	  test	  of	  treatment	  effect,	  specifically	  the	  test	  for	  a	  difference	  in	  differences,	  i.e.	  Ho:	  Change	  CGT	  =	  
Change	  IPT	  vs.	  Ha:	  change	  CGT	  >	  Change	  IPT.	  
C	  Standardized	  change	  values	  for	  continuous	  outcomes	  are	  plotted	  in	  Figures	  1	  –	  3.	  
D	  Expressed	  as	  numbers	  (%).	  n	  =	  32	  in	  CGT	  due	  to	  missing	  data.	  
E	  	  Difference	  in	  %	  change	  between	  groups	  
F	  In	  additional	  tests	  using	  the	  non-­‐parametric	  Wilcoxin	  signed	  rank	  test,	  the	  treatment	  effect	  was	  marginally	  significant,	  p=.06.	  
	  
Antidepressant Use As A Moderator  
A significant interaction was found between antidepressant use and treatment group on 
HRSD (p = .06). Table 3 shows the resulting summary of pre and post-treatment scores on the 
HRSD by treatment group and antidepressant status. CGT was significantly better at decreasing 
depression than IPT. This difference was most pronounced for the subgroup of participants not 
taking medication where CGT reduced depression but IPT did not (p = .0001).  The difference 
was less pronounced for those taking medication, where both groups had a reduction in 
depression scores with a greater change in CGT (p = .13). There was no interaction between 
antidepressant use and any of the other ancillary outcomes.  
Table 3. Pre and Post Treatment Scores on HRSD by Treatment Group & Antidepressant Status 
 No Antidepressants Antidepressants 
 CGT (n=14) IPT (n=20) CGT (n=19) IPT (n=14) 
 M (SD) P-value M (SD) P-value M (SD) P-value M (SD) P-value 
Pre 18.6 (6.1)  16.3 (6.2)  19.8 (7.1)  17.6 (7.8)  
Post 8.7 (5.0)  16.5 (9.8)  12.9 (9.8)  13.9 (6.3)  
Diff 9.9 (6.7) .0000 -.2 (6.6) .55 6.9 (8.2) .0009 3.7 (7.6) .046 




This study extends research by Shear et al. (2005) by identifying additional outcomes of 
CGT including a reduction in anxiety, depression, grief-related avoidance, guilt/self-blame and 
negative thoughts about the future. These symptoms can be conceptualized as the complicating 
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problems that prolong acute grief. Among the variables where the difference in change between 
groups was statistically significant, effect sizes for the difference between the treatments were in 
the medium to high range (.34 - .99), which is particularly striking since the control group (IPT) 
was an active treatment condition that has proven to be efficacious in the treatment of 
depression.  The main finding that CGT produced significantly greater change in the range of 
additional outcomes reported here is important because it provides us with more information 
about what is changing within the patient during or as a result of treatment.  These variables may 
in fact be mediators of CGT or just added benefits and should be explored as such.  
The target symptoms assessed in this report are typical of mood and anxiety disorders, 
yet they had not responded to previous treatment and did respond to a targeted treatment for CG 
(85% of the 243 individuals seeking treatment for CG in the parent study had previously sought 
treatment for grief (Shear et al., 2011) and had not improved). This suggests that CGT is 
producing unique benefits.   
The significant reduction in symptoms of anxiety, depression (including negative 
thoughts about the future and guilt/self-blame) and avoidance of reminders of the loss supports 
the theoretical model of CGT, which posits that complicating thoughts, emotions and behaviors 
can interfere with the normal grieving process.  For example, negative emotions such as guilt, 
which are continuously activated in CG, can keep the person focused on the painful aspects of 
the death and the consequences of the loss (Shear, 2012). Negative thoughts about the future can 
similarly keep the patient stuck in a constant state of worry about bad things that might happen 
and a conviction that life can never be good again. Avoidance behavior can interfere with the 
emotional processing necessary for grief to proceed.  
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Two of the outcomes reported by Shear et al. (2005) in addition to a reduction in CG 
were depression, measured by the BDI and anxiety, measured by the BAI. While depression 
decreased more in CGT than IPT, the difference in anxiety reduction was not statistically 
significant1.  In the present study, these measures were broken down into subscales (cognitive 
and somatic) in order to explore whether treatment group affected cognitive vs. somatic aspects 
of depression and anxiety differently. Surprisingly, results showed better outcomes for CGT than 
IPT on the somatic subscale of the BDI and not on the cognitive subscale where both groups saw 
a significant reduction. The stronger outcome on the somatic subscale may indicate that the 
differential impact of CGT vs. IPT on depression is more strongly related to change in the 
somatic components of the disorder. Given that CGT does not target somatic symptoms directly, 
this is an interesting finding and may signify that the physiological dysregulation experienced by 
people with CG is amenable to the techniques used in CGT.  It is also plausible that as symptoms 
of CG come down (via techniques used in CGT), somatic symptoms of depression such as loss of 
energy, irritability, change in appetite, loss of interest in other people and loss of pleasure start 
to abate as well. 
A seemingly contradictory finding is that the cognitive subscale of the BAI showed 
significantly better results for CGT while the somatic subscale of the BAI showed no difference 
between groups. This result is opposite that of the BDI subscales where the somatic component 
responded more in CGT than IPT.  The cognitive subscale of the BAI included items related to 
worrying about the future such as fear of the worst happening, fear of losing control, and fear of 
dying. It is possible that CGT does better at addressing these symptoms than IPT whereas the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  In	  this	  study,	  the	  analysis	  of	  the	  treatment	  effect	  difference	  of	  the	  BAI	  total	  score	  was	  significant	  at	  the	  .05	  level.	  
  
  32
   
	   	   	  
cognitive aspects of depression, which are focused more on the past such as feeling like a failure, 
guilty feelings, self-criticalness and punishment feelings respond well to both treatments.  
The difference in change between groups on the HRSD is also noteworthy, with a 
significantly greater change in CGT than IPT. This result matches that of the other depression 
measures (BDI and MDD) and the effect size of the difference between the groups of 1.2 is equal 
to that of the difference between groups on the BDI measure of depression. While the change in 
depression as measured by the HRSD was significant, the mean score post treatment (11.2) was 
still within the mild clinical range (7 – 17 is mild, 18 to 24 moderate and >25 is severe), although 
just barely for those in CGT not taking antidepressants (post-treatment score = 8.7).  The HRSD 
was also the only measure where outcome differed by antidepressant use. CGT did better than 
IPT in lowering depression only for those not taking medication. This finding is in direct contrast 
to that of the parent study where antidepressant use marginally increased the response rate in 
CGT.  The fact that antidepressant use was an added benefit to CGT participants in reducing 
grief symptoms but not in reducing depression supports the assertion by grief researchers that 
grief and depression are distinct disorders.  
The inclusion of change in ‘poor sleep quality due to bad dreams’ as an ancillary 
outcome of CGT was based on prior research showing that the majority of CG patients exhibit 
clinically significant sleep disturbance (Germain et al., 2005). While CGT does not target bad 
dreams or nightmares, it does target cognitive schemas related to the death and the deceased that 
cause patients distress. That bad dreams decreased more in CGT than IPT is consistent with the 
hypothesis that changes in cognitive schemas that occur during CGT persist during dreaming 
(Germain et al., 2013).  This finding may be particularly relevant for military veterans who have 
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CG, many of whom have related bad dreams. CGT could be particularly helpful for this 
population. 
This study has several limitations.  Using a sample of completers rather than the intent-
to-treat group reduced the sample size from 95 to 69, which may have reduced the power to 
detect differences between the treatment groups. It also leaves open the possibility that those 
who dropped out of treatment were different from those who stayed in, compromising the 
generalizability of the findings.  However, an analysis of the variables at baseline showed no 
difference between completers and drop-outs on any of the measures. Another limitation is that 
the SCI-CG and GRAQ were introduced later in the study, reducing the sample size for the 
variables created from these scales even further from 69 to about 55. This may have affected the 
results with respect to self-blame where the difference in means was marginally significant (.08) 
and avoidance where the difference between groups was statistically significant for only one of 
the three measures.  
This study examined ancillary outcomes in the treatment of CG and found that CGT is 
effective in reducing anxiety and depressive symptoms (including negative thoughts about the 
future and guilt) as well as grief-related avoidance and bad dreams in addition to CG. These 
symptoms are manifestations of complicating problems targeted by CGT. As such, the current 
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This study is an exploration of possible mediators in a previously reported efficacy study 
of Complicated Grief Treatment (CGT) (Shear et al., 2005). Complicated grief (CG) is a recently 
identified syndrome that is impairing and associated with a negative course without treatment. 
CG affects roughly 7% of bereaved people (Kersting, 2011). While not currently a diagnosis in 
the DSM-IV, CG can be reliably identified by administering the Inventory of Complicated Grief 
(ICG)	  (Prigerson et al., 1995)	  more than six months after the death of a loved one and using a 
cut-off score of 30. As outlined by Shear et al. (2005, 2011), CG is characterized by a sense of 
disbelief regarding the death; anger and bitterness over the death; intense longing and yearning 
for the deceased with recurrent pangs of painful emotions; preoccupation with thoughts of the 
loved one, often including distressing intrusive thoughts related to the death; and extensive 
avoidance of reminders of the loss. 
CGT is the first targeted treatment for this condition that was manualized and tested in a 
formalized randomized controlled trial. The treatment is based on an attachment theory 
framework for understanding bereavement, grief and mourning and the complications that 
impede natural healing. The goals of CGT are to reduce grief complications and to rejuvenate the 
natural healing process.   
In a randomized controlled trial testing the efficacy of the treatment, CGT was found to 
be more effective in treating complicated grief than IPT (intent-to-treat response rate: 51% vs. 
28% p = .02)	  (Shear et al., 2005). Among treatment completers, the response rate in the CGT 
group was 66% vs. 32% in IPT, p = .006.  The number needed to treat was 4.3 for modified 
intent-to-treat and 2.9 for completers. Among completers, CGT was also more effective in 






The current paper reports results of mediation analyses carried out to explore the 
mechanisms of action of CGT. In a prior analysis of the completer sample (see paper 1), this 
author identified secondary outcomes of CGT that are hypothesized to mediate the reduction in 
grief symptoms: a reduction in guilt/self-blame, negative thoughts about the future, anxiety and 
depression (intense negative emotions) and avoidance of reminders of the loss. About half of the 
study participants were taking antidepressant medication and those who were had a markedly 
greater rate of completion in CGT (91% vs. 58%) (Simon, 2008). Therefore, analyses were 
conducted to determine whether the mediating process between treatment and outcome differed 
for those taking antidepressants (moderated mediation).  
Methodology for establishing mediation has been developed and the approach advocated 
by Baron and Kenny is widely accepted (Baron & Kenny, 1986). The primary task is to 
demonstrate a strong association between the intervention and the mediator and between the 
mediator and the outcome. It is also necessary to establish that change in the mediator preceded 
change in the outcome (Johansson & Hoglend, 2007). This study examines the association 
between five putative mediators and the reduction in grief symptoms, using the method proposed 
by Baron and Kenny.  It also addresses temporal precedence by examining the association 
between change in the mediator early in treatment and subsequent change in outcome.    
Conceptual underpinnings of CGT 
Normal grief is an instinctual psychobiological response to the death of a loved one 
(Bowlby, 1980).  When a loved one dies, the attachment system is activated, causing an acute 
grief response characterized by intense separation distress (yearning and longing for the 
deceased, intense sadness, preoccupation with thoughts and memories of the deceased and loss 






loss, feeling lost and disoriented, intrusive images and avoidance of reminders). The loss also 
triggers a mourning process in which the bereaved slowly comes to terms with the death and 
restores his/her interest in life. Healing usually proceeds in fits and starts, as a person confronts 
the finality and consequences of the loss and begins to redefine her/his life so that it has purpose 
and meaning and the possibility for joy and satisfaction. Over time, grief is transformed from an 
acute, dominant form to one that resides in the background, no longer interfering with daily life. 
Psychological issues can complicate and derail the healing process. Most typically these 
include counter-factual thinking around troubling aspects of the death (e.g. blaming oneself or 
others for how the person died) or consequence of the death (e.g. life has no purpose or meaning 
without the loved one); avoidance behaviors; and problems with emotion regulation. This results 
in the syndrome of complicated grief. CGT works to identify and resolve the complicating issues 
(e.g. acceptance vs. counterfactual thinking, reducing avoidance, supporting emotion regulation) 
in order to facilitate the natural healing process of fully acknowledging the finality and 
consequences of the loss and re-envisioning life with meaning and satisfaction.  
Overview of parent study 
For a detailed description of methodology, see Shear et al. (2005).  Recruitment of 
participants was carried out between 2001 and 2004 in Pittsburgh, PA. Participants were 
included if they had a loss at least 6 months prior, a score of >30 on the Inventory of 
Complicated Grief (ICG) (Prigerson et al., 1995) and identified grief as their most important 
problem. Participants were randomly assigned to receive 16 sessions of CGT or IPT.  Medication 
was permitted as long as the participant had been on it for 3 months and at a stable dose for 
greater than 6 weeks. Therapists (either masters or doctoral level) were trained in either CGT or 






analysis of a randomly selected subset of session segments showed that the two treatments could 
be distinguished (Wilsey et al., 2006).  Self-report measures and questionnaires administered by 
independent evaluators (blinded to treatment assignment) were used to collect data at baseline, 
during treatment and post-treatment follow-up. The primary outcome measure was the Clinical 
Global Impression of Improvement Scale (CGI). Response to treatment was defined as a rating 
of 1 or 2 (very much or much improved). Additional outcome measures included the Inventory 
of Complicated Grief (ICG), Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI) 
and Work and Social Adjustment Scale (WSAS).  
The control condition, IPT, is a short-term manualized treatment	  (Weissman et al., 2000) 
that focuses on work in one or more of four interpersonal problem areas that are thought to be 
associated with mood symptoms; these include grief, interpersonal disputes, role transition and 
interpersonal deficits. Most of the IPT treatments focused on grief alone or with one of the other 
problem areas. 
The treatment condition, CGT, was also delivered according to a treatment manual and 
had yielded positive results in a prior pilot study (Shear et al., 2001). Its beginning phase 
included psycho-education about the difference between normal and complicated grief as well as 
the dual process model of adaptive coping, which includes a focus on both adaptation to loss and 
restoration of a satisfying life (Stroebe & Schut, 1999). Personal goals were also introduced in 
this early phase.  The middle phase of CGT continued the focus on both loss and restoration in 
tandem. Setting it apart from IPT, CGT employs specific techniques to address CG symptoms. 
An “imaginal revisiting” exercise is used where the patient is asked to visualize and recount the 
story of when s/he first learned of the death (in the present tense) while being audio-taped and 






procedures include an “imaginal conversation” with the deceased, working with memories and 
pictures and “situational revisiting” (graded exposure to avoided situations). Restoration-focused 
procedures include working with aspirations and goals, rewards and self-care and situational 
revisiting. These components help the patient to envision a life with meaning and purpose and 
the possibility for joy and satisfaction. 
Method 
Sample 
The current study examined treatment completers only (n=69) in order to test preliminary 
hypotheses about mechanisms of action of CGT among those who complete the full course of 
treatment. Completers did not differ from drop-outs on any of the baseline measures.  
Dependent Variables 
Clinical Global Improvement (CGI): The CGI scale	  (Guy, 1976) is a single Likert-type 
rating from 1 to 7 where 1 through 3 indicate very much, much and minimally improved 
respectively; 4 indicates no change and 5 through 8 indicate minimally, much and very much 
worse respectively.  The independent evaluator derived the CGI score from the therapist report 
of global improvement, a brief narrative justifying the therapist rating and self-report 
assessments from the final session.  A CGI rating of 1 or 2 (very much or much improved) 
qualified the participant as a treatment responder.   
Inventory of Complicated Grief (ICG):  The 19-item Inventory of Complicated Grief 
assesses symptoms of CG. This scale has been utilized in various studies of CG and has good 
internal validity and reliability (alpha = .94) and six-month test-retest reliability (r = .80).  A 






1995). This measure was administered at baseline, weeks 1 – 16, post treatment and 6-month 
follow-up.  
Work and Social Adjustment Scale (WSAS): The WSAS is a modification of a scale 
developed by Hafner and Marks, consisting of 0 to 8 point ratings of the extent to which grief 
symptoms interfere in five areas of daily functioning: work, home management, private leisure, 
social leisure, and family relationships.  It is a well-validated and widely used measure	  (Mundt et 
al., 2002).  This measure was administered at baseline, weeks 1 – 16, post treatment and 6-month 
follow-up.  
Putative Mediators  
Selection of putative mediators was based on the theoretical model of CGT (see above), 
which posits that grief complications need to be addressed in order for the natural healing 
process to take place. These complications include dysfunctional thoughts, ineffective emotion 
regulation and excessive avoidance. Assessment instruments from the parent study were 
reviewed to identify candidate mediators that might be operating in CGT. These included change 
in self-blame/guilt related to the death or the deceased, negative thoughts about the future, 
anxiety, depression and avoidance behavior. In a prior analysis by this author, described in paper 
1, at least one variable measuring each of these constructs was associated with treatment group at 
the p<=.05 level or if marginally significant, with a treatment difference effect size =>.30. 
Guilt/self-blame about the death or the deceased: This variable was derived from the 
Structured Clinical Interview for Complicated Grief (SCI-CG). This SCID-like interview was 
developed for the parent study and has been utilized in several studies of CG by Shear et al.’s 
research group. A composite of the following items was used: Have you had guilty or self-






something either when _____ was alive, or at the time he/she died, that you think might have 
helped? Do you have the idea that you could have prevented this death, even though you know it 
isn’t very rational? Internal consistency for this composite variable was high (Cronbach’s α = 
.86).   
Negative thoughts about the future: This variable was measured by one item on the Beck 
Depression Inventory (BDI), a widely used, well-validated 21-item self-report instrument used to 
assess the severity of depression	  (Beck et al., 1979).  This item asks the respondent to select the 
statement that best describes the way he/she has been feeling in the past week: I am not 
particularly discouraged about the future; I feel discouraged about the future; I feel I have 
nothing to look forward to; I feel that the future is hopeless and that things cannot improve. 
Anxiety: Two variables were used to measure anxiety. The first was the total score on the 
Beck Anxiety Inventory (BAI), a 21-item, well-validated instrument used to measure clinical 
anxiety	  (Beck et al., 1988). This measure has good internal consistency and test-retest reliability.  
The second variable was derived from a composite of items used to measure the cognitive 
aspects of anxiety identified by Hewitt and Norton who found two factor loadings for the BAI; 
cognitive and somatic (Hewitt & Norton, 1993). The items that loaded highest on the cognitive 
factor (and low on the somatic factor) include: fear of the worst happening, terrified, nervous, 
fear of losing control, fear of dying, and scared. Internal consistency for the composite variable 
(in this sample) was high (Cronbach’s α = .89).  The somatic subscale, which included items 
related to bodily sensations associated with anxiety such as dizziness, sweating and racing heart, 
was not included in this study since there was no association between somatic anxiety and 






Depression: Three variables were used to measure depression. The first was the total 
score on the Beck Depression Inventory (BDI), a widely used, well-validated 21-item self-report 
instrument used to assess the severity of depression	  (Beck et al., 1979). 
The second variable was derived from a composite of items used to measure the cognitive 
aspects of depression identified by Steer et al., who found two factor loadings for the BDI; 
cognitive and somatic-affective (Steer et al., 1999). Cognitive aspects of depression include: 
pessimism, past failure, guilty feelings, punishment feelings, self-dislike, self-criticalness, 
suicidal thoughts or wishes, crying and worthlessness.  Internal consistency for the composite 
variable (in this sample) was high (Cronbach’s α = .86).   
The third variable was derived from the somatic-subscale of the BDI and includes: loss of 
pleasure, loss of interest, indecisiveness, loss of energy, irritability, change in appetite, tiredness 
and fatigue, and loss of interest in sex. Lack of concentration also loaded high on this factor but 
was not included in this analysis because it is not in the 21-item version of the BDI. Internal 
consistency for the composite variable (in this sample) was high (Cronbach’s α = .81).   
Avoidance: Two variables were used to measure change in avoidance.  The first was the 
total score on the Grief Related Avoidance Questionnaire (GRAQ)	  (Shear et al., 2007). This 15-
item self-report questionnaire was developed and tested by Shear’s research team to assess the 
level of avoidance of common situations and activities following the death.  The scale has good 
psychometric properties (α = .87) and CG patients endorse a range of scores on the scale.  
The second variable was derived from the SCI-CG (described above). A composite of 
two items from the SCI-CG was used to measure avoidance behavior: Do you avoid activities, 
people, places, or objects that remind you of ____?  and Do you feel reluctant to talk about  







The Fisher’s exact test was used to compare baseline characteristics of categorical 
variables and two-tailed t-tests were used to compare baseline characteristics for continuous 
variables.  Correlations between potential mediators were examined with pairwise correlations of 
mediators at baseline as well as correlations between their change scores. 
Mediation analysis was performed according to the Baron and Kenny (1986) method of 
testing mediation	  	  (see Figure 1). The method consists of the following four components:  
1. There is a main effect of treatment (Path A). This analysis was performed by the parent 
study	  (Shear et al., 2005) and was repeated in the present study by using logistic and multiple 
regression analyses of CGI, ICG and WSAS on a dichotomous treatment indicator.  
2. Treatment is related to change in the mediator (Path B). This analysis was performed 
in a previous study by this author (see paper 1). Change in the mediators was operationalized by 
creating a change variable equal to the score at baseline – the score at post-treatment (week 16), 
with higher scores reflecting greater symptomatology.  
3. Change in the mediator is related to change in outcome (Path C) controlling for 
treatment assignment. Change in outcome is equal to the score at baseline – score at post 
treatment (week 16). This analysis was performed using logistic and multiple regression 
analyses. A test for interaction between treatment group and mediators was also done to examine 
whether the relationship between mediator and outcome differed by treatment group. To test for 
moderated mediation, multiple regression analysis was used to examine the interaction between 
putative mediators and antidepressant use as it affects grief symptoms.  
4. Effect of treatment on outcome is significantly weakened when statistically controlling 






controlling for the putative mediators (same model as step 3). Each mediator was tested in a 
separate regression rather than testing them all together in one model. Percentage of treatment 
effect explained by the mediator was calculated as the original coefficient – the new coefficient / 
original coefficient. Examining each mediator separately was done in order to explore whether 
each variable alone appears to play a role in the treatment effect found between CGT and IPT. 
The goal was to point the way for future research to investigate whether these variables emerge 
as mediators in a subsequent RCT, rather than to examine which mediator was the most salient.  
Further analysis was conducted to test for temporal precedence. An early change variable 
was created for each mediator equal to the score at week 1 – the score at week 8.  A subsequent 
change variable was created for each outcome equal to the score at week 9 – the score at post 
treatment. This analysis could not be done for the variables using the SCI-CG since this measure 
was only collected at baseline and post treatment. For the avoidance variables measured by the 
GRAQ, early change is equal to the score at week 1 – the score at week 10 since this measure 
was not collected at week 8. Multiple regression analysis was used to test whether early change 
in the mediator (week 1 through 8) predicted subsequent change in the outcome (week 9 through 
post treatment), controlling for treatment group.  
All analyses were performed using STATA version 11 software and statistical 















The sample was 84% female, 74% Caucasian, 22% African-American, 3% Asian, with a 
mean age of 48.4 years.  Mean ICG score was 44.8.  Comorbid mood or anxiety disorders were 
common. Forty-six percent had current major depressive disorder (MDD), 52% current 
posttraumatic stress disorder (PTSD), 8.8% current panic disorder (PD), 6% current obsessive-
compulsive disorder (OCD) and 3% current social phobia disorder. Thirty-four out of 69 (49%) 
were on at least one antidepressant medication. There were no significant differences in 
demographic characteristics or putative mediator variables between the two randomized groups 
at baseline.  
Correlations between potential mediators 
 Correlations between potential mediators at baseline showed that depression was highly 






moderately correlated with negative thoughts about the future (r=.42) and avoidance-GRAQ 
(r=.33). Correlations between mediator change scores revealed that change in depression was 
moderately correlated with change in all of the other variables, guilt (r=.31), negative thoughts 
about the future (r=.55), anxiety (r=.36) and avoidance-GRAQ (r=.37). Change in avoidance was 
moderately correlated with guilt (r=.29) and negative thoughts about the future (r=.30). See 
Tables 1 and 2. 
Table 1. Correlations Between Mediators at Baseline 










Guilt 1.0      
Negative Thoughts About Future .03 1.0     
Anxiety (BAI Total) .11 .42 1.0    
Depression (BDI Total) .16 .72 .66 1.0   
Avoidance-GRAQ .14 .07 .33 .36 1.0  
Avoidance-SCI-CG .14 -.01 .11 .15 .60 1.0 
 
Table 2. Correlations Between Mediator Change Scores 










Guilt 1.0      
Negative Thoughts About Future .15 1.0     
Anxiety (BAI Total) -.01 .23 1.0    
Depression (BDI Total) .31 .55 .36 1.0   
Avoidance (GRAQ) .29 .30 .03 .37 1.0  
Avoidance (SCI-CG) .20 .14 .03 .20 .55 1.0 
 
Main Treatment Effect (Path A) 
As reported by Shear et al. (2005), the main treatment effect among completers of CGT 
on outcome was statistically significant (CGI: OR=4.01 (2.05), p=.01 (95% confidence interval 
(CI), 1.5 – 10.9); ICG: B=8.34 (.3.1), p=.01 (95% CI, 2.13 – 14.55); WSAS: B=5.08 (2.4), p=.04 
(95% CI, .21 – 9.95)).  
Association Between Treatment Group and Change in Putative Mediators (Path B) 
For at least one variable of each construct (e.g. guilt, avoidance, depression), the 
association between treatment group and change in the mediator was statistically significant. For 






paper 1. Variables were selected if they had an effect size => .3 and were related to the 
conceptual model of CGT. 
Association Between Change in Putative Mediators and Change in Outcome (Path C) 
A summary of the regression results for the three outcomes is in Table 3.  For at least one 
variable of each construct (e.g. guilt, avoidance, depression), there was a significant association 
between change in the mediator and a reduction in grief (on either the CGI, ICG or WSAS). A 
test for interaction between treatment group & putative mediator yielded no significant results 
with the exception of Anxiety – Cognitive Subscale on the WSAS. With regard to this variable, there	  was	  an	  additional	  positive	  relationship	  between	  change	  in	  anxiety	  and	  outcome	  for	  the	  CGT	  group,	  B=1.65,	  p	  =	  .01. 
Table 3. Regression Results: Assoc. Between Change in Mediators and Grief Outcomes (Path C)  
 OutcomesA  
Mediator Variables CGI ICG WSAS 











Guilt/Self-Blame  1.2 (.15) 1.7 (.69)* .31 (.12)* 1.1 (.52)* .25 (.12)* 
          SCI-CG (n=56)      
Neg. Thoughts About the Future 2.3 (.92)* 6.6 (2.1)** .36 (.11)** 4.7 (1.6)** .33 (.12)** 
          BDI (n=69)      
Anxiety       
          BAI total (n=69) 1.1 (.03) .23 (.18) .15 (.12) .04 (.14) .04 (.12) 
          Cognitive Subscale  1.1 (.08) 1.1 (.38)**	   .32 (.11)** .32 (.32) .13 (.12) 
Depression       
          BDI total (n=69) 1.2 (.05)** .87 (.18)*** .52 (.11)*** .76 (.13)*** .59 (.10)*** 
          Cognitive Subscale 1.3 (.12)** 1.3 (.43)** .33 (.11)** .99 (.33)** .34 (/11)** 
          Somatic-Affective Subscale 1.3 (.12)** 1.6 (.36)*** .46 (.11)*** 1.4 (.27)*** .53 (.10)*** 
Avoidance       
         GRAQ (n=54) 1.1 (.04)** .53 (.12)*** .50 (.12)*** .48 (.09)*** .59 (.11)*** 
         SCI-CG (n=56) 2.1 (.52)** 3.4 (1.2)**	   .34 (.12)** 3.4 (.82)*** .45 (.11)*** 
Note. p* <= .05, p** <= .01, p*** <= .001 
A Controlling for treatment group 
B Change variables were standardized before running regressions calculated as change variable – mean / SD. 
 
Effect of Treatment on Outcome When Controlling for the Mediator (Path D) 
As predicted, the treatment effect of CGT on outcome was significantly weakened when 
controlling for the putative mediators (see Table 4).  Full mediation was demonstrated for guilt, 






demonstrated for negative thoughts about the future, cognitive aspects of anxiety and depression 
(cognitive and somatic-affective) (see Table 5).  





























Guilt/Self Blame          
     SCI-CG (n=56) 4.0 (2.4)* 1.2 (.15) 0% 4.3 (3.3) 1.7 (.69)* 48% 2.1 (2.5) 1.1 (.52)* 59% 
          
Negative Thoughts 
About the Future 
         
     BDI (n=69) 3.2 (1.7)* 2.3 (.92)* 16% 5.8 (3.0) 6.6 (2.1)** 30% 3.3 (2.4) 4.7 (1.64)** 35% 
          
Anxiety           
    BAI total (n=69) 3.59 (1.9)* 1.1 (.03) 8% 7.6 (3.2)* .23 (.18) 9% 4.9 (2.5)* .04 (.14) 4% 
    Cognitive Subscale 3.4 (1.8)* 1.1 (.04) 12% 6.3 (3.0)* 1.1 (.38)** 25% 4.5 (2.5) .32 (.32) 11% 
          
Depression           
   BDI total (n=69) 2.7 (1.5) 1.2 (.05)*** 28% 3.7 (2.8) .87 (.18)*** 56% 1.0 (2.1) .76 (.13)*** 80% 
   Cognitive Subscale 4.1 (2.3)** 1.3 (.12)** 2% 7.2 (2.9)* 1.3 (.43)** 14% 4.2 (2.3) .99 (.33)** 17% 
   Somatic Subscale 3.4 (1.9)* 1.3 (.20)** 12% 5.8 (2.8)* 1.6 (.36)*** 30% 2.8 (2.1) 1.4 (.27)*** 45% 
          
Avoidance           
    GRAQ  (n=54) 2.7 (1.8) 1.1 (.04)** 28% 3.8 (3.1) .53 (.12)*** 54% .53 (2.3) .48 (.09)*** 90% 
    SCI-CG (n=56) 2.9 (1.7) 2.1 (.52)** 23% 3.3 (3.3) 3.4 (1.2)** 60% .80 (2.2) 3.4 (.82)*** 84% 
Note. p* <= .05, p** <= .01, p*** <= .001 
B=unstandardized coefficient 
M=putative mediator 
A Calculated as log original OR – log new OR / log original OR 
B Calculated as original Coef – new Coef / original Coef 
 
Table 5. Mediators of Outcome in CGT 
 Full Mediation Parital Mediation 
 CGI ICG WSAS CGI ICG WSAS 
Guilt/Self-Blame        
      SCI-CG (n=56)  √ √    
Negative thoughts about the future       
      BDI (n=69)  √ √ √   
Anxiety        
      BAI total (n=69)       
      Cognitive Subscale     √  
Depression        
      BDI total (n=69) √ √ √    
      Cognitive Subscale   √  √  
      Somatic-Affective Subscale   √ √ √  
Avoidance        
      GRAQ Total (n=54) √ √ √    
      SCI-CG (n=56) √ √ √    
*Note: Full mediation is established when the effect of treatment on outcome is no longer statistically significant when 










Summary of regression results are in Table 6. Temporal precedence was established for 2 
of the 5 mediators (avoidance and depression) when regressing early change in the mediator 
(weeks 1 - 8) on subsequent change in grief (weeks 9 - post treatment). An early reduction in 
avoidance predicted subsequent reduction in grief (WSAS), B = .30 (.12), p = .015 compared 
with the overall association between change in avoidance and change in grief of .48 (.09), p = 
.000. An early reduction in depression predicted subsequent change in grief (ICG), B = .36 (.15), 
p = .017, compared with the overall association between change in depression and change in 
grief of .87 (.18), p = .000. Additionally, an early reduction in the cognitive aspects of depression 
predicted subsequent change in grief (ICG), B = 1.0 (.33), p= .003, compared with the overall 
association between change in cognitive – depression and change in grief of 1.3 (.43), p = .005). 





Negative Thoughts About the Future   
          BDI (n=69) 1.18 (1.4) .21 (1.2) 
Anxiety     
         BAI Cognitive Subscale (n=69) .31 (.27)  
Depression    
         BDI total (n=69) .36 (.15)* .17 (.13) 
         Cognitive Subscale 1.0 (.33)** .37 (.29) 
         Somatic - Affective Subscale .60 (.39) .28 (.33) 
Avoidance    
         GRAQ totalE  (n=54) .18 (.15) .30 (.12)* 
Note. p* <= .05, p** <= .01, p*** <= .001 
A Only mediators that were statistically significant in the mediator analyses are included. Guilt (SCI-CG) and Avoidance (SCI-
CG) were not included because the SCI-CG was only collected at baseline and post treatment. CGI as an outcome was not 
included because this measure was only collected at post treatment. Regressions controlled for treatment group. 
B Early change in mediator = score at week 1 – score at week 8 except for the Avoidance (GRAQ) variable which = score at week 
1 – score at week 10. 
C Subsequent change in outcome = score at week 9 – score at post treatment.   
D B = unstandardized coefficient 
E Avoidance (GRAQ) was measured at week 10 in the CGT group only (n=27). 
  
Moderated Mediation 
There was an interaction between antidepressant use and the cognitive aspects of anxiety 






(response to treatment) was stronger for those not taking antidepressants than for those taking 
antidepressants.    
Discussion 
This study extends the efficacy findings of CGT by examining the putative mediators and 
mechanisms of action of the treatment.  Building on the Shear et al. study, which found a main 
effect of CGT over IPT in reducing grief, this study tested five putative mediators of CGT and 
found all to be statistically significant.  The finding that a reduction in guilt/self-blame related to 
the death or the deceased, negative thoughts about the future, cognitive aspects of anxiety, 
depression and avoidance behavior mediate the relationship between treatment group and 
outcome supports the model of CGT, which posits that complications in thoughts, emotions and 
behavior interrupt the normal grief process and need to be targeted in order for healing to occur. 
The strongest mediator to emerge in this study is avoidance, whose role in reducing 
symptoms of complicated grief cannot be overstated. Both avoidance variables were significant 
for full mediation and accounted for a very high percentage of the treatment effect (54% and 
60% on the ICG and 90% and 84% on the WSAS). While early reduction in avoidance (GRAQ) 
predicted subsequent change in the WSAS (grief impairment scale), it did not predict change on 
the ICG. It is possible that change in avoidance occurred before change in the ICG but that both 
changed earlier than week 10. It also possible that because this variable was only measured at 
week 10 in the CGT group and not in the control, the sample size was too small to detect a 
significant relationship between early change in avoidance and subsequent change in outcome. It 
should be noted that the temporal relationship between the change in avoidance and change in 






Since overall change in avoidance did differ by treatment group, it is plausible that early change 
in avoidance also differed by treatment group but this requires further testing.  
Reducing cognitive and behavioral avoidance is one of the key objectives of CGT as 
these coping strategies, if used in excess, can become a significant impediment to the healing 
process	  (Shear, 2010).  Cognitive avoidance is addressed in CGT through exposure-like 
techniques such as imaginal revisiting (retelling the story of the death) and situational revisiting, 
which help the patient to confront painful emotions connected to the loss and to reflect on the 
finality and consequences of the death.  
Behavioral avoidance is addressed through situational revisiting exercises that focus on 
identifying and confronting situations that the patient has been avoiding since the death. In doing 
this work, the patient learns to monitor the amount of distress associated with exposure to a 
particular situation and to gradually confront the avoided situation until the intensity of distress is 
reduced.  
The finding that avoidance reduction (via exposure-like techniques) mediates outcome is 
also consistent with the findings of prior studies. Boelen and colleagues found that exposure 
therapy alone was more effective than cognitive restructuring alone in treating CG and that 
adding exposure therapy to cognitive restructuring led to more improvement than adding 
cognitive restructuring to exposure therapy (Boelen et al., 2007).  In a further analysis of this 
data, the authors found that stronger reduction in CG severity was significantly associated with 
reductions in negative cognitions and avoidance (Boelen et al., 2011). Bryant tested CBT with 
and without exposure (to memories of the death and loss) in a sample of 79 patients with 
prolonged grief disorder (PGD) and found that the CGT/Exposure treatment resulted in superior 






(Bryant, 2012). While change in avoidance was not measured in this study, it is plausible that the 
exposure techniques, which focused on memories of the death and the loss, reduced symptoms 
via a reduction in avoidance. 
Negative thoughts about the future also emerged as a strong mediator (fully mediating 
outcome on the ICG and WSAS and partially mediating outcome on the CGI). This finding 
supports the restoration focus of CGT. Helping the patient to envision a future that feels 
satisfying and joyful without the deceased is a main element of the treatment. There was no 
evidence in this analysis, however, that a reduction in negative thoughts between weeks 1 and 8 
predicted subsequent reduction in grief, leaving open the question about temporal precedence. It 
is possible that a reduction in grief preceded the reduction in negative thoughts. It is also possible 
that the change in negative thoughts about the future occurred within the first few sessions, 
which was not captured in this analysis. Identifying the directionality of this relationship requires 
further testing. 
Self-blame/guilt specific to the death or the deceased fully mediated outcome on both the 
grief (ICG) and impairment (WSAS) scales and accounted for 48% and 59% of the treatment 
effect on the ICG and WSAS respectively. Guilt specific to the death or the deceased, 
conceptualized in the CGT model as maladaptive self-blaming counterfactual thoughts, is 
directly targeted in the treatment. This variable was not measured for temporal precedence 
because the SCI-CG was only collected at baseline and post treatment. Interestingly, change in 
generic guilt (as measured by one item on the BDI) also differed by treatment group and was 
associated with a reduction in grief.  It is possible that targeting grief-specific guilt reduced more 
generic depressive guilt feelings as well. However, we cannot be certain of the directionality of 






The reduction of depression as a mediator of CGT is an interesting finding. It could be 
argued that both CGT and IPT have antidepressant effects, however these results showed the 
reduction of depression to be greater in CGT and to account for a large percentage of the 
treatment effect: 28%, 56% and 80% on the CGI, ICG and WSAS respectively.  While 
depression and CG are distinct disorders, some of the symptoms overlap. It is possible that the 
BDI is capturing CG symptoms, accounting for its strong showing as a mediator. The cognitive 
and somatic-affective subscales were equally strong, suggesting that change in both categories of 
depressive symptoms are associated with the change in grief and may contribute to the success of 
CGT. The temporal precedence analysis showed that early change in depression (both the total 
score and the cognitive subscale) predicted subsequent change in grief, supporting the hypothesis 
that a reduction in depressive symptoms (particularly cognitive aspects) contributes to the 
reduction in grief. It should also be noted that correlations between the mediator change scores 
revealed that change in depression was moderately to highly correlated with all of the other 
variables. This suggests that there is overlap between them, which makes is difficult to determine 
which mediator had the strongest effect. 
Of the anxiety variables, only the cognitive subscale emerged as a mediator of outcome 
(ICG). This variable included: fear of the worst happening, terrified, nervous, fear of losing 
control, fear of dying and scared. (When examined separately, fear of dying emerged as the only 
item that differed by treatment group.) Cognitive anxiety was a partial mediator of outcome, 
accounting for 25% of the treatment effect. There was no evidence that the cognitive aspects of 
anxiety predicted subsequent change in grief. It is therefore possible that the change in grief 
occurred first and that this reduced anxiety or as stated above, the change in anxiety occurred 






oriented emotion (whereas depression is past oriented), the finding that anxiety may have 
changed subsequent to a reduction in grief would be consistent with that of negative thoughts 
about the future. 
Regarding moderated mediation, the findings indicate that antidepressant use affects the 
mediating role of anxiety (cognitive) on outcome in CGT. For those taking antidepressants, the 
reduction in cognitive anxiety played less of a role in grief reduction than for those not taking 
antidepressants. This suggests that the antidepressants may have played more of a role in 
reducing anxiety in CGT than the psychotherapy and supports the hypothesis put forward by 
Simon et al. (2008) that antidepressants dampen the amygdala. In their secondary analysis of the 
parent study examining the role of medication in CGT, Simon et al. speculated that 
antidepressants may have helped CGT patients cope with some of the more activating 
components of CGT, allowing them to stay in treatment longer. 
The main limitation of this study is that mediation was an exploratory aim in the parent 
study and did not include prospectively defined assessments for the putative mediators. As such, 
this analysis employs measures that may not adequately capture the specific constructs identified 
in this paper. One of the main targets of CGT is emotion regulation and this was not measured by 
any of the instruments. An examination of changes in anxiety and depression may reflect 
changes in emotion regulation but this is merely speculative. Future research on mediation in 
CGT should include a measure for emotion-regulation that captures the patient’s ability to 
tolerate difficult emotions or manage behavior in the context of emotional distress. 
As an exploratory study, each mediator was examined separately. While this allows for 
closer scrutiny of each construct in order to detect potential mediating effects, it also has the 






interpreted as hypothesis generating rather than hypothesis testing. Future research should 
incorporate putative mediators into one statistical model in order to determine which variables 
mediate outcome when controlling for all the others.   
Another limitation is that the sample size for some of the measures may have been too 
small to detect differences.  The SCI-CG and GRAQ were introduced later in the study, reducing 
the sample size on these measures from 69 to about 55.  An analysis of the participants missing 
these measures compared to the rest of the sample showed no differences, minimizing the 
possibility that the smaller sample was skewed. However, the small sample size on these 
measures, may have affected the results with respect to the avoidance and guilt variables in 
particular.  It is striking that the avoidance and guilt/self-blame variables, despite the small 
sample size, were strong mediators of outcome. This supports the theory that addressing 
complicating thoughts and behaviors are important to reducing complicated grief (Shear et al., 
2007; Shear, 2012).  
Another limitation is that temporal precedence was addressed by examining scores at 
only three time points (baseline, mid-treatment and post-treatment). It is very possible that 
change in the mediator within the first few weeks predicted subsequent change in grief and this 
would not have been captured in these analyses. Additionally, the SCI-CG was only 
administered at baseline and post treatment, which prevented the temporal precedence analysis 
for the guilt and avoidance variables measured by the SCI-CG. Finally, the results of this study 
are only applicable to those who complete CGT since the analyses did not include the entire 
intent-to-treat sample. 
This study identified five putative mediators of outcome in a randomized controlled trial 






Kenny method of identifying mediators and also took into account temporal precedence, which is 
rare in mediation studies of psychotherapy. These results can be used to further test the 
mediating role of these variables by manipulating them in a subsequent RCT, thereby yielding 
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Therapeutic alliance is most commonly defined as the agreement between patient and 
therapist on therapeutic goals, consensus on treatment tasks and the relationship bond (Bordin, 
1979). It has also been referred to as the “quality and strength of the collaborative relationship 
between client and therapist” (Horvath & Bedi, 2002).  
The role of the alliance in psychotherapy has been debated for decades. Zuroff & Blatt 
(2006) identified four prevailing arguments about the contribution of the therapeutic relationship 
to psychotherapy outcome. The first view, endorsed by cognitive-behavioral therapists (Beck, 
1983), is that a positive alliance is necessary for the effectiveness of any therapy but does not 
drive therapeutic change as much as specific techniques. The second view, endorsed by 
humanistic therapists such as Carl Rogers, is that a positive alliance is the driving force behind 
therapeutic change, irrespective of any specific type of treatment. The third view is that the 
alliance is causally related to change in outcome but its effects depend on a specific set of 
techniques such as transference interpretation, which operate through the alliance in 
psychoanalytic psychotherapy. The fourth position is that the alliance is neither a necessary 
ingredient nor a causal factor in outcome and that outcome is due solely to specific therapeutic 
techniques.   
In order to show that any component of psychotherapy accounts for symptom change, 
whether the variable is common to all treatments such as therapeutic alliance or specific to a 
particular treatment type such as cognitive restructuring in cognitive therapy, mediation analysis 
must be performed (within the context of a randomized controlled study). This entails showing 
that there is a main effect of treatment, that treatment is related to an intermediary variable 






diminished when controlling for the mediator (Kazdin, 2007). From this analysis, we can 
determine how much of the treatment effect is accounted for by the variable in question.  
Alliance has largely been examined in terms of its correlation with outcome, not its role 
as a mediator of treatment effects. It has been identified in the psychotherapy literature as one of 
the most salient components of treatment, accounting for significantly more of the variability in 
outcome (5 to 7%) than specific ingredients such as treatment techniques (1%) (Wampold, 
2001). This view is supported by studies that examine the correlation between alliance (as 
measured by one of several standard instruments) and the primary treatment outcome using 
either simple correlation or cross-sectional regression (Horvath & Symonds, 1991; Martin, 2000; 
Horvath & Bedi, 2002; Horvath et al., 2011; McLeod, 2011) More recently, researchers have 
used longitudinal designs to examine alliance at different time points, controlling for earlier 
symptom change (Barber et al., 2000; Kaufman et al., 2005; Zuroff & Blatt, 2006; Beckner et al., 
2007). 
The most recent meta-analysis of alliance in individual psychotherapy by Horvath et al. 
(2011) included 201 studies and found an aggregate correlation between alliance and outcome of 
.275, accounting for 5 to 7% of the variance. Recent studies have also shown that the correlation 
between alliance and outcome holds true across treatment types, patient characteristics, 
measurement scales, raters, time of alliance (early, mid or late), outcome measures, publication 
source, research design, and researcher allegiance (Horvath et al., 2011; Fluckiger, 2012).  
Horvath et al. (2011) investigated the impact of six potential moderators of alliance and outcome 
and found the aggregate alliance-outcome correlations in each category to be statistically 
significant beyond p<.001. The authors concluded that the impact of alliance on outcome is 






when it is assessed, the way the outcome is evaluated and the type of therapy involved.” In a 
nutshell, alliance matters. 
Only a handful of published studies on the alliance-outcome relationship have failed to 
confirm these results.  Alliance did not predict outcome, when controlling for early change, in a 
sample of 54 elderly depressed patients treated in behavioral, cognitive or brief dynamic 
psychotherapy (Gaston et al., 1991). No relationship was found between alliance and outcome in 
a sample of 252 cocaine-dependent outpatients treated in cognitive, dynamic or drug counseling, 
also controlling for early change in outcome (Barber et al., 1999). Alliance did not predict 
outcome in a sample of 25 depressed outpatients treated with cognitive therapy (Feeley, 1999). 
This research group did find, however, that a concrete set of therapist actions, measured early in 
treatment by the Collaborative Study Psychotherapy Rating Scale (CSPRS), did predict 
subsequent change in depression, suggesting that specific ingredients drive outcomes more than 
common factors such as alliance. The view that specific ingredients drive outcome is also 
supported by numerous studies in the literature (DeRubeis & Feeley, 1990; Piper et al., 1991; 
Barber et al., 1996; DeRubeis & Crits-Christoph, 1998; Shear et al., 2005; Mark et al., 2011). 
As noted by Kazdin (2007), the correlation between alliance and outcome does not by 
itself show that alliance plays a causal role in symptom improvement. Feeley and colleagues 
have suggested that alliance may in fact be caused by early symptom improvement rather than 
the other way around (Feeley, 1999). DeRubies and Feeley (1990) found that alliance measured 
later in treatment was predicted by prior symptom reduction. In a subsequent study by Feely et 
al. (1999), this finding was not replicated. Nonetheless, researchers argue that when examining 
the relationship between alliance and outcome, directionality must be assessed (Johansson & 






ignored temporal precedence. Alliance has been measured mid-treatment and correlated with 
symptom change from beginning to end (Castonguay et al., 1996; Gaston et al., 1998; Beckner et 
al., 2007). Or alliance is averaged across the duration of treatment and related to overall 
symptom change (Krupnick et al., 1996; Gaston et al., 1998; Abouguendia et al., 2004).  Change 
early in treatment and subsequent change are thus confounded because the predicted outcome 
incorporated symptom change that occurred before the alliance was measured.   
Zuroff & Blatt (2006) took temporal precedence into account by evaluating the 
relationship between two components of the therapeutic relationship (perceived positive 
relationship with the therapist (measured at session 2) and patient contribution to the alliance 
(measured at session 3)) and subsequent symptom change while controlling for any potential 
confounding of early clinical improvement (Zuroff & Blatt, 2006). They also examined a wide 
range of patient characteristics that could account for the positive effects of the therapeutic 
relationship on outcome. In this study, 191 depressed outpatients were randomly assigned to 12 
sessions of CBT, IPT, medication treatment or placebo. Data was collected at intake, weeks 4, 8, 
12 and 16 and at follow-up. Few significant differences were found among the three active 
treatment conditions (Elkin et al., 1989), however the perceived positive relationship with the 
therapist predicted positive therapeutic outcome. The authors concluded that the therapeutic 
relationship contributes directly to positive therapeutic change, irrespective of specific technique.  
While this study comes closer to demonstrating a causal relationship between alliance and 
outcome based on the study design, it still falls short of a full mediation analysis where the 
superiority of one treatment over another is explained at least in part by the alliance.  
Many variables contribute to alliance including patient factors (e.g. age, race, gender, 






experience and training) and treatment factors (e.g. type of treatment, specific techniques, 
frequency of sessions) as well as interactions between them. For example, one treatment 
approach might work better for patients with a particular disorder than another. In addition to 
addressing the issue of causality, the examination of alliance as a mediator of treatment outcome 
also helps to parse out treatment factors (how the treatment is delivered) from the overall alliance 
affect. A prospective randomized controlled study controls for patient-related variables though it 
does not address therapist-related variables or interactions of patient, therapist and treatment 
variables. 
This author identified one study where alliance (in addition to five other variables) was 
examined as a potential mediator of treatment outcome (Kaufman et al., 2005). In an RTC 
comparing CBT to a life skills control condition for adolescents with depression and conduct 
disorder, alliance (measured at week 3) was found to be statistically higher in the life CBT group 
but was not related to treatment outcome. Alliance was therefore not found to mediate the 
treatment effect of CBT while another mediator, negative thoughts, was. 
The present study examines the role of alliance in the treatment of complicated grief 
(CG). Data was utilized from completers of a randomized controlled trial (RCT), which found 
that complicated grief treatment (CGT) is more effective than Interpersonal Psychotherapy (IPT) 
in reducing symptoms of CG (Shear et al., 2005). In examining the role of alliance as a 
contributor to post-treatment outcome, the present study sought to address the following 
questions: 1) Does early working alliance (measured at week 4 by the WAI) predict greater 
subsequent improvement in CG symptoms or associated impairment at post treatment 
(controlling for earlier symptom change)? And 2) Does alliance fully explain the improvement in 






hypothesized that the working alliance would be associated with symptom reduction (outcome) 
but would not fully account for the treatment difference in outcome in CGT (mediation). 
Overview of parent study 
A detailed description of methodology is available in a previously published paper (Shear 
et al., 2005). Briefly, recruitment of participants was carried out through media advertisement, 
professional and self-referral. Participants were included if they had a loss at least 6 months 
prior, a score of >30 on the Inventory of Complicated Grief (ICG)	  (Prigerson et al., 1995) and 
identified grief as their most important problem. Medication was permitted as long as the 
participant had been on it for 3 months and at a stable dose for greater than 6 weeks. Participants 
were randomly assigned to receive 16 sessions of CGT or IPT.  Therapists (either masters or 
doctoral level) were trained in either CGT or IPT and received ongoing supervision. Therapy 
sessions were audio taped for adherence. Self-report measures and questionnaires administered 
by independent evaluators (blinded to treatment assignment) were used to collect data at 
baseline, during treatment and post-treatment follow-up. Response to treatment was defined as a 
rating of 1 or 2 (very much or much improved) on the Clinical Global Impression of 
Improvement Scale (CGI). Additional outcome measures included the Inventory of Complicated 
Grief (ICG), Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI) and Work and 
Social Adjustment Scale (WSAS). Therapeutic alliance was measured by the Working Alliance 
Inventory (WAI). 
For a detailed description of each treatment, see Shear et al. (2005). Briefly, IPT 
treatment is based on a model that postulates a bidirectional relationship between interpersonal 
problems and mood. The therapist and patient collaborate to select one or two of four 






include grief, interpersonal disputes, role transition and interpersonal deficits. Most of the IPT 
treatments focused on grief alone or with one of the other problem areas.  
CGT used an attachment theory model of grief and mourning. It specifically targeted 
relief of complicating problems and facilitation of the natural healing process. CGT focused on 
both loss and restoration in tandem. Loss-related procedures included an “imaginal revisiting” 
exercise in which the patient tells the story of when s/he first learned of the death in the present 
tense and then listens to an audiotape of this at home in between sessions. Other loss-focused 
procedures included an “imaginal conversation” with the deceased, working with memories and 
pictures and “situational revisiting.” Restoration-focused procedures included working with 
aspirations and goals, rewards and self-care and situational revisiting. Both treatments were 
administered in 16 individual weekly sessions. 
Method 
Sample 
The current study examined treatment completers only (n=69; n=35 for CGT and n=34 
for IPT) in order to test hypotheses about the alliance-outcome relationship among those who 
complete the full course of treatment. Completers did not differ from drop-outs on any of the 
baseline measures. For CGT, 13/49 (27%) dropped out of treatment and for IPT, 12/46 (26%) 
dropped out of treatment.  
Dependent Variables 
Clinical Global Improvement (CGI): The CGI scale (Guy, 1976) is a single Likert-type 
rating from 1 to 7 where 1 through 3 indicate very much, much and minimally improved 
respectively; 4 indicates no change and 5 through 8 indicate minimally, much and very much 






of global improvement, a brief narrative justifying the therapist rating and self-report 
assessments from the final session.  A CGI rating of 1 or 2 (very much or much improved) 
qualified the participant as a treatment responder.   
Inventory of Complicated Grief (ICG):  The 19-item Inventory of Complicated Grief 
assesses symptoms of CG. This scale has been utilized in various studies of CG and has good 
internal validity and reliability (alpha = .94) and six-month test-retest reliability (r = .80). In the 
initial study, a score of 25 defined the upper quartile of scores and was associated with 
significant impairment in functioning	  (Prigerson et al., 1995). This measure was administered at 
baseline, weeks 1 – 16, post treatment and 6-month follow-up.  
Work and Social Adjustment Scale (WSAS): The WSAS is a modification of a scale 
developed by Hafner and Marks, consisting of 0 to 8 point ratings of the extent to which grief 
symptoms interfere in five areas of daily functioning: work, home management, private leisure, 
social leisure, and family relationships.  It is a well-validated and widely used measure	  (Mundt et 
al., 2002).  This measure was administered at baseline, weeks 1 – 16, post treatment and 6-month 
follow-up.  
Independent Variable 
Working Alliance: Alliance was measured by the Working Alliance Inventory (WAI), a 
12-item self-report instrument that measures three aspects of the therapeutic relationship: 1) 
agreement between client and therapist on therapy goals (e.g. my therapist and I are working 
towards mutually agreed upon goals); 2) agreement between client and therapist on the tasks of 
therapy (e.g. my therapist and I agree about the things I will need to do in therapy to help 
improve my situation); and 3) the interpersonal bond between client and therapist (e.g. my 






choices ranging from never to always. This measure is widely used and has good internal validity 
and reliability (α = .92)	  (Byrd et al., 2010).   The WAI was collected at weeks 4, 8 and 12.  The 
week 4 alliance score was used in this study as a measure of early alliance in order to avoid 
possible confound of early symptom change.  
Statistical analysis 
Comparisons between completers in each treatment group on baseline characteristics 
used Fisher’s exact test for categorical variables and two-tailed t-tests for continuous variables.  
Two-tailed t-tests were used to examine the association between treatment group and alliance at 
week 4. Statistical significance was set at p<=0.05.  Effect size (ES) for the difference in alliance 
between groups was calculated by dividing the mean difference between groups by the pooled 
standard deviation.    
The relationships between alliance and outcomes were first analyzed using simple 
correlations in order to allow comparisons with results reported in the literature (Horvath et al., 
2011). These tested the relationship between early alliance (week 4) and subsequent change in 
outcome (week 5 to 16) on the ICG and WSAS as well as the CGI at week 16.  
Logistic and multiple regression analyses were then performed to examine whether early 
alliance (week 4) predicted subsequent change in outcome (week 5 to 16), controlling for early 
change in outcome (week 1 to 3) and treatment group. Subsequent change in outcome was 
measured in three ways: ICG change from week 5 to week 16, WSAS change from week 5 to 16, 
and simply the CGI at week 16. When CGI was the outcome, no control for early change in 
outcome was possible.  
A test for interaction between treatment group and alliance was also done to examine 






Mediation analysis was performed according to guidelines proposed by Baron and Kenny 
(1986) and modified by a MacArthur Foundation Network subgroup (Kraemer et al., 2008) 
utilizing the alliance score at week 4 as the potential mediator. The following components must 
be present (see Figure 1):  
1. There is a main effect of treatment (Path A).  
2. Treatment is related to change in the mediator (Path B).  
3. Change in the mediator is related to change in outcome (Path C).  
4. Change in the mediator must precede change in the outcome. 
 
Kraemer et al. (2002) proposed a revision to step 3 so that change in the mediator can but 
does not have to be directly related to the outcome (Path C).  If there is no direct relation but an 
interaction between treatment and mediator on outcome, mediation can still be established. This 
would mean that the relation between mediator and outcome is different depending on the 
treatment group, implying that the treatments work through different mechanisms (i.e. moderated 
mediation). In the presence of moderated mediation, differential indirect effects are estimated 
depending on whether treatment is CGT or IPT since Path C depends on CGT or IPT (Preacher 
et al., 2007). The mediation effect is quantified by taking the beta from Path B and multiplying it 
by one of the estimates for Path C that are obtained under each of the two treatment groups (i.e. 
from the interaction model). The ratio of this indirect effect (in each treatment group) can then be 
compared to the overall treatment effect (Path A) to measure the percentage of treatment effect 
explained by the working alliance. 



















The completer sample was 84% female, 74% Caucasian, 22% African-American, 3% 
Asian, with a mean age of 48.4 years.  Mean ICG score was 44.8.  Mean WSAS score was 21.2. 
Comorbid mood or anxiety disorders were common. Forty-six percent had current major 
depressive disorder (MDD), 52% current posttraumatic stress disorder (PTSD), 10% current 
panic disorder (PD), 3% current social phobia disorder, and 6% current obsessive-compulsive 
disorder (OCD). Thirty-four out of 69 (49%) were taking antidepressant medication. There were 
no significant differences in demographic or clinical baseline characteristics between the two 
randomized groups at baseline.  
Association Between Treatment Group and Alliance (Path B) 
Alliance at week 4 was significantly higher in the CGT group than in IPT (M = 70.4, SD 
= 9.5 in CGT vs. M = 65.5, SD = 11.6, p=.05). See Figure 2. The effect size of the difference 













Association Between Alliance and Outcome 
Simple correlations revealed an overall correlation between alliance and outcome of .24 
(p = .04) on the CGI, .20 (p = .10) on the ICG and .24 on the WSAS (p = .05). While the 
correlations between alliance and outcome were significant on the CGI and WSAS for the whole 
sample, the correlations were no longer significant when examined by treatment group. On the 
ICG, the result was the reverse; the alliance-outcome correlation was insignificant for the whole 
sample, but significant for the CGT group alone. See Table 1. for a summary of correlations by 
treatment group.  
Table 1. Simple Correlations Between Alliance and Outcomes by Treatment Group 
 CGT IPT 
 CGI ICG WSAS CGI ICG WSAS 
Alliance (WAI) .26 .34* .31 .11 -.11 .04 
Note. p* <= .05, p** <= .01, p*** <= .001 
 
(Path C)  
The regression equations, controlling for earlier change in outcome (weeks 1 to 3) on the 
ICG and WSAS revealed no statistically significant relationship between alliance and subsequent 






= .13, p = .33; WSAS: B = .17, SE = .11, p = .13). There was, however, a statistically significant 
interaction between alliance and treatment group on outcome (ICG: B = .57, p=.03). The 
interaction indicated that there was a significant positive relationship between alliance and 
outcome within the CGT arm, but a null relationship between alliance and outcome in the IPT 
arm, see Figure 3. A summary of regression results by treatment group is in Table 2. 
Table 2. Regression Results: Association Between Alliance and Outcomes by Treatment GroupAB 















Alliance (WAI) 1.06 (.04) 35 .46 (.22) 35* .37 (.20) 35 1.02 (,03) 34 -.10 (.14) 34 .02 (.11) 34 
Note. p* <= .05, p** <= .01, p*** <= .001 
A Controlling for treatment group and prior symptom change 
B Non-standardized units 
 
Figure 3. Relationship Between Alliance and Change in Grief by Treatment Group 
 
 
Alliance Mediating Outcomes 
According to both the Baron and Kenny and MacArthur approaches, there must be a 
statistically significant relationship between treatment group and mediator for mediation to be 
established (Path B). This was true for alliance measured at week 4.  Although alliance did not 






treatment group and alliance on outcome (ICG) indicated a significant Path C for the CGT group, 
fulfilling the MacArthur criteria for mediation. The indirect effect of treatment on ICG through 
alliance for CGT = 5.02 * .46 = 2.3 ICG points and for IPT 5.02 * -.10 = -0.5 ICG points.  
Previously Shear et al. (2005) found the total effect of CGT vs. IPT on ICG to be 8.3 ICG points, 
therefore 28% (calculated as 2.3/8.3 = .28) of this effect can be explained by the indirect effect 
through alliance gained within the CGT group. 
Discussion 
This study examined the role of therapeutic alliance in explaining the differential efficacy 
of 16 sessions of CGT compared to IPT in relieving symptoms of CG. Early alliance did not 
predict subsequent change in CG symptoms in the sample as a whole when controlling for early 
symptom change; however it did predict change in ICG in the CGT group and accounted for 
roughly one-third of the difference in outcome on the ICG between the two treatments. 
The significant correlation between alliance and outcome of .24 on the CGI and WSAS is 
consistent with prior research, but slightly lower than the most recent meta-analysis, showing an 
aggregate correlation of .275 (Horvath et al., 2011). When controlling for early symptom change 
and treatment group using logistic and multiple regression however, the overall associations 
between alliance and outcome became statistically insignificant. These results should caution us 
to think more critically about the simple correlations reported in the alliance literature. 
It is only through mediation analysis, however, that we know whether alliance accounts 
for the difference in treatment effects. The results presented here show that early alliance is 
related to treatment group, that it is associated with subsequent outcome in CGT and that it 






found to be operating in CGT (identified by this author in paper #2, i.e. avoidance, depression or 
guilt) alliance accounts for a modest but statistically significant portion of the treatment effect. 
The idea that the alliance-outcome relationship varies by treatment type, was also 
supported in a study that found that alliance predicted improvements in depression in cognitive-
behavioral therapy (CBT) but not in emotion-focused therapy (EFT) (Beckner et al., 2007). The 
authors of this study were surprised that alliance was more strongly related to outcome in CBT 
than EFT and speculated that it may have been the transparent process, structure, clear goals and 
expectations of CBT, which accounted for this difference. 
Structure and transparency may also partly explain the differential impact of alliance on 
outcome in CGT vs. IPT. Patients feel themselves to be collaborators when the therapist lays out 
the theoretical model of the treatment, the goals and the activities, all the while asking for input 
and feedback. Each session follows a format that is explicitly shared with the patient at the 
beginning of the hour and repeated each week.  This process builds trust, reduces anxiety and 
gives the patient a feeling of mutual responsibility for the treatment. 
Also important is the therapeutic stance.  CGT emphasizes a “companionship alliance” 
from the very first session (Shear, 2013). This entails a very supportive and active therapeutic 
role, a statement by the therapist early in the treatment about being the patient’s companion 
during the treatment process, some disclosure of personal information by the therapist, and 
conveyance of a strong belief in the treatment and in the patient’s capacity to overcome the 
obstacles that are interfering with the normal grieving process. In IPT, these attitudes may be 
communicated but in a less explicit way. 
The third factor, which may explain the findings in this study, is the psycho-educational 






complicated grief and how CGT works to clear out the obstacles that have kept them from 
moving on. Patients feel enormous relief and hope for change when they understand what they 
have been going through, that they are not alone in this process and that there is a treatment 
specifically designed to help them. In IPT, complicated grief symptoms are explained in the 
context of depression rather than as a separate syndrome requiring a unique treatment approach. 
This may not elicit the same level of hope and/or motivation in the patient as in CGT.  
Results from this analysis showed that the interaction between early alliance and 
treatment group accounted for some of the treatment effect difference but not all of it. This 
supports the view that alliance is a necessary component of the treatment but not the only 
important ingredient.  In a prior study carried out by this author, it was shown that 5 other 
variables mediated outcome in CGT, including the reduction in guilt/self-blame related to the 
deceased or the death, negative thoughts about the future, cognitive anxiety symptoms, 
depression and avoidance (see paper 2).  These variables are closely related to targets within the 
treatment, supporting the view that specific techniques matter a great deal.  Taken as a whole, 
these findings suggest that a good working alliance, in conjunction with specific techniques make 
CGT successful in the treatment of CG. 
This study has several limitations. Most notably, there was no baseline measure of 
alliance.  Since alliance develops over time and cannot be measured before the treatment starts, 
getting a baseline measure is not possible. Therefore an assumption was made that alliance was 
the same in both treatment groups at baseline and “changed” or developed by week 4. This 
assumption was based on randomization and the fact that participants did not differ on any of the 






change (ICG and WSAS) did not differ between groups during weeks 1 through 3, making it 
unlikely that alliance at week 4 was affected by differences in early symptom change.  
Generalizability of the findings may be compromised by the use of completers rather than 
the intent-to-treat group, leaving open the possibility that those who dropped out of treatment 
were different from those who stayed in. An analysis of the variables at baseline, however, 
showed no difference between completers and drop-outs.  
Another limitation is that alliance was measured by only one instrument and by only one 
rater.  Although prior research has shown that self-reported alliance is most predictive of 
outcome, it would also be useful to examine whether therapist-reported alliance or a different 
measurement tool would produce different results. Another limitation is that this study did not 
control for any patient factors that may have affected the alliance.  Variables such as attachment 














Abouguendia, M., Joyce, A., Piper, W., & Ogrodniczuk, J. (2004). Alliance as a mediator of 
expectancy effects in short-term group psychotherapy. Group Dynamics: Theory, 
Research, and Practice, 8(1), 3-12.  
Barber, J., Connolly, M. B., Crits-Christoph, P., Gladis, L., & Siqueland, L. (2000). Alliance 
predicts patients' outcome beyond in-treatment change in symptoms. Journal of 
Consulting and Clinical Psychology, 68(6), 1027-1032.  
Barber, J., Crits-Christoph, P., & Luborsky, L. (1996). Effects of therapist adherence and 
competence on patient outcome in brief dynamic therapy. J Consult Clin Psychol, 64(3), 
619-622.  
Barber, J., Luborsky, L., Christoph-Crits, P., Thase, M. E., Weiss, R., Frank, A., et al. (1999). 
Therapeutic alliance as a predictor of outcome in treatment of cocaine dependence 
Psychotherapy Research, 9(1), 54-73.  
Beck, A. (1983). Cognitive therapy of depression: New perspectives In J. E. Barrett (Ed.), 
Treatment of depression: Old controversies and new approaches. New York: Raven. 
Beckner, V., Vella, L., Howard, I., & Mohr, D. (2007). Alliance in two telephone-administered 
treatments: Relationship with depression and health outcomes. Journal of Consulting and 
Clinical Psychology, 75(3), 508-512.  
Bordin, E. S. (1979). The generalizability of the psychoanalytic concept of the working alliance. 
Psychotherapy: Theory, Research, and Practice, 16, 252-260.  
Byrd, K. R., Patterson, C. L., & Turchik, J. A. (2010). Working alliance as a mediator of client 
attachment dimensions and psychotherapy outcome. Psychotherapy Theory, Research, 
Practice, Training, 47(4), 631-636.  
Castonguay, L. G., Goldfried, M. R., Wiser, S., Raue, P. J., & Hayes, A. M. (1996). Predicting 
the effect of cognitive therapy for depression: a study of unique and common factors. J 
Consult Clin Psychol, 64(3), 497-504.  
DeRubeis, R., & Crits-Christoph, P. (1998). Empirically supported individual and group 






DeRubeis, R., & Feeley, M. (1990). Determinants of change in cognitive therapy for depression. 
Cognitive therapy and research, 14, 469-482.  
Elkin, I., Shea, M., Watkins, J., Imber, S., Sotsky, S., & Collins, J. (1989). NIMH Treatment of 
Depression Collaborative Research Program: General effectiveness of treatments. 
Archives of General Psychiatry, 46, 971-982.  
Feeley, M., DeRubeis, R., Gelfand, L. (1999). The temporal relation of adherence and alliance to 
symptom change in cognitive therapy for depression. Journal of Consulting and Clinical 
Psychology, 67(4), 578-582.  
Fluckiger, C., Del Re, A.C., Wampold, B.E., Symonds, D., Horvath, A.O. (2012). How central is 
the alliiance in psychotherapy? A multilevel longitudinal meta-analysis. Journal of 
Counseling Psychology, 59(1), 10-17.  
Gaston, L., Marmar, C. R., Gallagher, D., & Thompson, L. W. (1991). Alliance prediction of 
outcome beyond in-treatment symptomatic change as psychotherapy processes. 
Psychotherapy Research, 1, 104-112.  
Gaston, L., Thompson, L., Gallagher, D., Cournoyer, L. G., & Gagnon, R. (1998). Alliance, 
technique, and their interactions in predicting outcome of behavioral, cognitive, and brief 
dynamic therapy. Psychotherapy Research, 8, 190-209.  
Guy, W. (1976). CGI Clinical Global Impressions ECDEU Assessment Manual for 
Psychopharmacology (Revised) (pp. 217-222): National Institute of Mental Health. 
Horvath, A., & Bedi, R. P. (2002). The alliance. In J. C. Norcross (Ed.), Psychotherapy 
relationships that work (pp. 37-69). Oxford, England: Oxford University Press. 
Horvath, A., Fluckiger, C., Del Re, A. C., & Symonds, D. (2011). Alliance in individual 
psychotherapy. Psychotherapy, 48(1), 9-16.  
Horvath, A., & Symonds, B. D. (1991). Relation between working alliance and outcome in 
psychotherapy: A meta-analysis. Journal of Counseling Psychology, 38(2), 139-149.  
Johansson, P., & Hoglend, P. (2007). Identifying mechanisms of change in psychotherapy: 






Kaufman, N., Rohde, P., Seeley, J., Clarke, G., & Stice, E. (2005). Potential mediators of 
cognitive–behavioral therapy for adolescents with comorbid major depression and 
conduct disorder. Journal of Consulting and Clinical Psychology, 73, 38-46.  
Kazdin, A. E. (2007). Mediators and mechanisms of change in psychotherapy research. Annual 
Review of Clinical Psychology, 3, 1-27.  
Kraemer, H., Kiernan, M., Essex, M., & Kupfer, D. (2008). How and why criteria defining 
moderators and mediators differ between the Baron & Kenny and MacArthur 
Approaches. Health Psychology, 27(2), 101-108.  
Krupnick, J. L., Sotsky, S. M., Simmens, S., Moyer, J., Elkin, I., Watkins, J., et al. (1996). The 
role of the therapeutic alliance in psychotherapy and pharmacotherapy outcome: findings 
in the National Institute of Mental Health Treatment of Depression Collaborative 
Research Program. J Consult Clin Psychol, 64(3), 532-539.  
Mark, H., Jerold, G., Jenelle, S.-M., & Joel, W. (2011). Therapeutic Interventions Related to 
Outcome in Psychodynamic Psychotherapy for Anxiety Disorder Patients. The journal of 
nervous and mental disease, 199(4), 217.  
Martin, D. J., Garske, J.P., Lewis, M.K. (2000). Relation of the therapeutic alliance with 
outcome and other variables: A meta-analytic review. Journal of Consulting and Clinical 
Psychology, 68, 438-450.  
McLeod, B. D. (2011). Relation of the alliance with outcomes in youth psychotherapy: A meta-
analysis. Clinical Psychology Review, 31, 603-616.  
Mundt, J. C., Marks, I. M., Shear, M. K., & Greist, J. H. (2002). The Work and Social 
Adjustment Scale: a simple measure of impairment in functioning. British Journal of 
Psychiatry, 180, 461-464.  
Murphy, R. (2009). How do psychological treatments work? Investigating mediators of change. 
Behaviour research and therapy, 47(1), 1.  
Piper, W. E., Azim, H. F., Joyce, A. S., & McCallum, M. (1991). Transference interpretations, 
therapeutic alliance, and outcome in short-term individual psychotherapy. Arch Gen 






Preacher, K. J., Rucker, D. D., & Hayes, A. F. (2007). Addressing moderated mediation 
hypotheses: Theory, methods, and prescriptions. Multivariate behavioral research, 42(1), 
185-227.  
Prigerson, H., Bierhals, A., Stanislav, K., Reynolds III, C., Shear, K., Day, N., et al. (1995). 
Inventory of complicated grief: a scale to measure maladaptive symptoms of loss. 
Psychiatry Research, 59, 65-79.  
Shear, K. (2013). Complicated grief treatment: instructional manual for NIMH grants 
(introductory phase). Unpublished manuscript, Columbia University. New York.  
Shear, K., Frank, E., Houck, P., & Reynolds III, C. (2005). Treatment of complicated grief: a 
randomized controlled trial. JAMA, 293(21), 2601-2608.  
Wampold, B. (2001). The Great Psychotherapy Debate: Models, Methods and Findings. 
Mahwah, NJ: Lawrence Erlbaum Associates, Inc. 
Zuroff, D., & Blatt, S. (2006). The therapeutic relationship in the brief treatment of depression: 
Contributions to clinical improvement and enhanced adaptive capacities. Journal of 
Consulting and Clinical Psychology, 74(1), 130-140.  
 
 
